



RHD Action

United to End
Rheumatic Heart Disease



GLOBAL STATUS OF BPG REPORT

**THE BENZATHINE
PENICILLIN G REPORT**

This report was overseen by Dr Rosemary Wyber from RHeACH on behalf of RHD Action.

Substantial contributions were gratefully received from:

Rosemary Wyber (RHeACH)
Timothy Johnson (RHeACH)
Jonathan Carapetis (RHeACH and Telethon Kids Institute)
Kimberly Davis (Menzies School of Health Research)
Katherine Gray (Telethon Kids Institute)
Shannon Marantelli (University of Western Australia)
Joanna Markbreiter (World Heart Federation)
Jeremiah Mwangi (World Heart Federation)
Susan Perkins (RHeACH)
Dianne Sika-Paotonu (Telethon Kids Institute)
Alastair White (World Heart Federation)
Yue Wu (Telethon Kids Institute)
Liesl Zühlke (RHeACH)

Additional case study information was received from:

Bruno Ramos Nascimento
(Universidade Federal de Minas Gerais, Brasil)
Antonio Luiz Pinho Ribeiro
(Universidade Federal de Minas Gerais, Brasil)

This work is copyright. You may download display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use, or use within your organisation. All other rights are reserved. Enquiries concerning reproduction and rights should be addressed to enquiries@rheach.org

This report was funded by Medtronic Foundation through support to RHD Action.

TABLE OF ABBREVIATIONS

ADR	Adverse drug reaction
API	Active pharmaceutical ingredient
BPG	Benzathine benzylpenicillin
EML	Essential Medicines List
EMLc	Essential Medicines List for Children
FDA	Food and Drug Administration
GAS	Group A streptococcus
IM	Intramuscular
INN	International Non-proprietary Names
IU	International units
MIC	Minimum inhibitory concentration
PEN	Package of Essential Noncommunicable Disease Interventions for Primary Health Care in Low Resource Settings
RHeACH	Rheumatic Heart Disease Evidence Advocacy Communication Hope
RF	Rheumatic fever
RHD	Rheumatic heart disease
TIPs	Tools for Implementing RHD Control Programs
UNICEF	United Nations Children's Emergency Fund
WHO	World Health Organization
WHF	World Heart Federation

CONTENTS

EXECUTIVE SUMMARY 4

BENZATHINE PENICILLIN G AND ITS USES 5

About BPG	6
Nomenclature	6
Structure and mechanism of action	7
Existing doses and formulations	8
BPG and Essential Medicines Lists	9
Clinical indications and doses	10
Syphilis	10
Syphilis in pregnant women	11
Congenital syphilis in neonates	12
Yaws and other Treponemal diseases	12
Treatment of group A streptococcal pharyngitis to prevent rheumatic fever	13
Prophylaxis against recurrent rheumatic fever	14
Treatment of skin sores and impetigo	16
Prophylaxis against infection in hyposplenism and asplenia	17
Prophylaxis against recurrent cellulitis	18
Lyme disease	18

SHORTAGES OF BPG 19

Overview	20
Australia	20
Brazil	21
China	21
India	22
South Africa	22
Timor-Leste	23
North America	23
Market vulnerabilities of BPG	24
Limited number of manufacturers for the active pharmaceutical ingredient	24
Poor visibility of demand	25
Overly aggressive price reduction practices in procurement	25
Fragmented and low volume markets	26
Business decisions by manufacturers	26

CHALLENGES FOR THE SUPPLY AND USE OF BPG 27

Adverse drug reactions to BPG	28
Systemic adverse reactions	28
Local adverse reactions	29
Quality and behaviour of BPG	31
Duration of action	31
Suitability for suspension	31
High rates of idiosyncratic adverse reactions	31
Antibiotic resistance	32

OPPORTUNITIES TO IMPROVE BPG 33

Options for product innovation or reformulation	34
Paediatric doses	34
Reduction of injection site pain	35
Longer acting formulations	35
Regulatory issues	36
The challenge of historic licensing data	36
Extending licensing to novel indications	36

ACTIONS AND RECOMMENDATIONS 37

Global actions	39
Regional actions	39
National actions	40
Local actions	40

ANNEXES AND REFERENCES 41

Annex A	42
Annex B	42
References	42

EXECUTIVE SUMMARY

Benzathine penicillin G (BPG) is an injectable antibiotic which provides a prolonged level of penicillin in the blood. There are two major global indications for BPG and a number of minor indications.

Syphilis and rheumatic heart disease are both major global public health challenges. Access to reliable, high quality formulations of BPG is a prerequisite for the treatment and control of both diseases. The importance of BPG is widely recognised, through inclusion on the World Health Organization’s Essential Medicines List and associated Special Indication Lists.

Despite considerable clinical need BPG has been the subject of widespread global shortages in recent years. Shortages have largely been attributed to difficulty securing quality assured active pharmaceutical ingredient for the manufacture of formulated product. Shortages of active pharmaceutical ingredient reflect the vulnerabilities of the global BPG market: procurement is fragmented by clinical indication, the number of manufacturers is small and total price of the drug is low.

BPG shortages interrupt treatment regimens and increase the use of more expensive, less effective drugs which may accelerate development of resistance in other organisms. A reliable supply of high quality BPG is urgently needed to provide gold standard care and to support rational use of antibiotics. However, BPG and other older, off-patent antibiotics have been licensed on historic data which is insufficient for contemporary regulatory standards. Improving the quality and supply of BPG requires collective global action to redevelop the drug: answering outstanding scientific questions, integrating new data in regulatory bodies and communicating clearly about how, when and why the drug should be used.

BPG remains an essential medicine and tangible, multi-stakeholder, steps are needed for it to be made safe and available to the vulnerable populations who need it most.

Major indications for BPG	<ul style="list-style-type: none">• Treatment of syphilis, particularly in pregnant women• Prophylaxis against rheumatic fever to prevent rheumatic heart disease
<i>The clinical demand for BPG is unequivocal: no equally efficacious alternative antibiotics exist, global disease burden is high and clinical outcomes of untreated disease are severe.</i>	
Minor indications for BPG	<ul style="list-style-type: none">• Primary prevention of rheumatic fever• Treatment of skin sores and pyoderma• Treatment of yaws, bejel and pinta• Prophylaxis in sickle cell disease• Prophylaxis following splenectomy• Prophylaxis of recurrent cellulitis
<i>The clinical demand for BPG is equivocal or varies by setting: BPG is indicated but alternative antibiotics exist, morbidity/mortality from the disease is low, systems for delivering the intervention are inadequate or use of BPG is under investigation for novel indications.</i>	

BENZATHINE
PENICILLIN G
AND ITS USES

About BPG	6
Nomenclature	6
Structure and mechanism of action	7
Existing doses and formulations	8
BPG and Essential Medicines Lists	9
Clinical indications and doses	10
Syphilis	10
Syphilis in pregnant women	11
Congenital syphilis in neonates	12
Yaws and other Treponemal diseases	12
Treatment of group A streptococcal pharyngitis to prevent rheumatic fever	13
Prophylaxis against recurrent rheumatic fever	14
Treatment of skin sores and impetigo	16
Prophylaxis against infection in hyposplenism and asplenia	17
Prophylaxis against recurrent cellulitis	18
Lyme disease	18

ABOUT BPG

Nomenclature

The World Health Organization (WHO) maintains a global list of International Nonproprietary Names (INN). The INN is a list of unique, global names of individual pharmaceutical substances, also known as the generic name of a drug.¹

Benzathine benzylpenicillin (BPG) has the following INN:

Latin - benzathini benzylpenicillinum

French - benzathine benzylpénicilline

Spanish - benzatina bencilpenicilina

Russian - бензатина бензилпенициллин

Arabic - بينزاثين بنزيلبنيسيلين

Chinese - 苄星青霉素

BPG is known by other names in some countries or in informal use. These may cause confusion, particularly when similar to other drug names. A list of synonyms for BPG is in Table 1.

Table 1: Synonyms for benzathine benzylpenicillin	
Benzathine penicillin G	Commonly abbreviated to BPG
Benzathine penicillin	
Penicillin G benzathine	Recognised by the United States Pharmacopeial Convention
Similar sounding drugs which are not BPG	
Benzylpenicillin	Penicillin G molecules without the benzathine molecule
Penicillin G	
Procaine benzyl penicillin	Penicillin G combined with the local anaesthetic agent procaine

Structure and mechanism of action

Penicillin G (otherwise known as benzylpenicillin, the precursor of BPG) is a bactericidal beta-lactam antibiotic which inhibits synthesis of the microbial cell wall during multiplication.² Penicillin G specifically inhibits the transpeptidase and D-alanine carboxypeptidase enzymes that would normally catalyse the final crosslinking step in the synthesis of the bacterial cell wall.^{3,4} The enzymatic inhibition interferes with peptidoglycan synthesis, creating defects in the cell wall.⁵ This affects the osmotic integrity of the cell wall, causing cell lysis and the eventual death of the microorganism.

The antimicrobial effect of penicillin was announced in the 1940 publication ‘*Penicillin as a chemotherapeutic agent*’ as a result of its effect on bacteraemia in rats.⁶ This new antibiotic produced impressive clinical outcomes in humans and was rapidly adopted to treat a wide range of infections. However, frequent injections were required to maintain therapeutic serum penicillin concentrations. Organic chemists focused on developing new formulations of penicillin G with predictable pharmacokinetic parameters. In 1951, Szabo, Edwards and Bruce synthesised a new penicillin salt N, N’-dibenzylethylenediamine dipenicillin, which became known as BPG.⁷

BPG is a crystalline powder produced by reacting two molecules of penicillin G with a single molecule of dibenzylethylenediamine base.^{8,9} The molecular structure of BPG is shown in Figure 1 and represented by the formula $C_{16}H_{20}N_2 \cdot (C_{16}H_{18}N_2O_4S)_2$.

Characterised by low aqueous solubility (200 units of penicillin per millilitre of water at 40°C), BPG forms a depot in muscle tissue following intramuscular injection, slowing its release into the bloodstream and producing prolonged therapeutic serum concentrations.^{8,10} After intramuscular injection, BPG is converted to penicillin G via hydrolysis. It is the hydrolytic conversion to penicillin G, combined with the slow absorption of BPG from the intramuscular injection site, which leads to the lower, but prolonged, plasma levels found in humans.

The same spectrum of antimicrobial activity is displayed by BPG as by aqueous crystalline penicillin G; both are active against most members of the Streptococci and Neisseriae genus, as well as many anaerobes and spirochetes.¹¹ The serum half-life of penicillin G after intramuscular administration is only 30 minutes, with levels undetectable after 3–6 hrs, while BPG has a much longer half-life of 4.1 days due to its low solubility.^{5,12} The excretion of penicillin G from the body occurs primarily via renal filtration and active tubular secretion, although excretion by the liver can also occur.^{2,5} In individuals with renal impairment, neonates and young infants, excretion of the drug is significantly delayed.²




Figure 1: Chemical structure of benzathine penicillin G

Existing doses and formulations

BPG is typically available in three doses, standardised to international units (IU), and listed in Table 2. The IU of penicillin was developed as a standard measure of potency when the drugs were developed. By definition, the IU of penicillin is the penicillin activity contained in 0.6 mg of the crystalline sodium salt of penicillin G.¹³

Worldwide, BPG is available in two main formulations, outlined in Table 3. The vast majority of the world use the powdered form of BPG.

Table 2: Standard doses of BPG		
International units (IU) of penicillin	Usual equivalent dose in grams of penicillin	Usual volume
600,000 IU	450 mg	Generally suspended in 2 ml of sterile diluent (or 1 ml of <i>Bicillin L-A</i> (Pfizer)) ¹⁴
1,200,000 IU	900 mg	Generally suspended in 3–5 ml of sterile diluent (or 2 ml of <i>Bicillin L-A</i> (Pfizer)) ¹⁴
2,400,000 IU	1.44 g	Generally suspended in 5 ml of sterile diluent (or 4 ml of <i>Bicillin L-A</i> (Pfizer)) ¹⁴

Table 3: Formulations of BPG		
Formulation	Lyophilised powder	Viscous liquid
Packaging	Vials	Pre-filled syringe
Manufacturer	Various trade and generic formulations [See annex B]	Pfizer, under the trade name <i>Bicillin L-A</i> ¹⁴
Cost of 1.2 million IU vial	Median global buyer price in 2014 = US\$0.22 ¹⁵	In Australia <i>Bicillin L-A</i> (Pfizer) costs AU\$29.33 (≈ US\$22)
Administration	Mixed with sterile diluent at point of care and injected intramuscularly	Administered directly from a preloaded syringe intramuscularly
Temperature stability	Temperature independent	Cold chain dependent Store in a refrigerator 2° to 8°C (36° to 46°F) ¹⁴
Availability	All other countries	Licensed/registered in Australia, New Zealand, Canada and the United States of America

BPG and Essential Medicines Lists

The WHO’s Essential Medicines List (EML) was established in 1977 and has been updated every two years since then. The list aims to draw together the medicines ‘that satisfy the priority health care needs of the population’, and which must be available within the health system at all times, in adequate amounts, as good-quality and affordable products.¹⁶

The WHO’s EML is often referred to as a ‘Model List’, as it is not designed as a global standard, but rather as a guide for the development of national or sub-national EMLs. Encouraged by the WHO, almost every country

has drawn up their own national EML tailored to their population’s specific health needs, and many of these can be accessed online.¹⁷ For mapping of BPG within National Essential Medicines Lists see Annex A.

BPG has been included on the WHO EML since its first iteration in 1977 and in every subsequent EML update.¹⁸

In addition to the core EML, WHO also identifies Special Indications Lists which supplements the WHO EML for specific populations. BPG is included on a number of supplementary EML lists, as outlined in Table 4.

Table 4: Essential Medicines Lists including BPG		
List	Organisation (latest revision)	Dose
Essential Medicines List¹⁶ First developed in 1977, the EML identifies medications which ‘satisfy the priority health care needs of the population’. The list is widely used by government and non-government organisations to prioritise and procure medicines.	WHO 2015	1.2 million IU powdered vial 2.4 million IU powdered vial
Essential Medicines Lists for Children (EMLc)¹⁹ Developed in 2007, the EMLc has addressed the unique medication needs of children, including paediatric dosage forms (i.e. suspensions, chewable tablets, soluble tablets). Of note, the EMLc does not include a 0.6 million IU dose of BPG, although the smaller dose is indicated for children in a number of guidelines.	WHO 2015	1.2 million IU powdered vial 2.4 million IU powdered vial
Essential Medicines for Reproductive Health²⁰ Developed in 2006, the Essential Medicines for Reproductive Health guide supports the inclusion of reproductive medicines in national formularies.	PATH WHO United Nations Population Fund 2006	2.4 million IU powdered vial
Interagency Emergency Health Kit (IEHK)²¹ The IEHK is designed to provide sufficient medication for a population of 10,000 people for three months in an emergency situation. A large number of government and non-government agencies compile emergency supplies using the IEHK framework.	Multi-agency 2011	50 x 2.4 million IU powdered vials

CLINICAL INDICATIONS AND DOSES

Syphilis

Syphilis is caused by infection with the *Treponema pallidum* bacterium. An estimated 18 million people aged 15–49 years had syphilis in 2012.²² Each year, an estimated 5.6 million people in the same age group acquire a new infection. Infection is acquired through sexual activity or blood transfusion. Some children are also infected via vertical transmission from mother to child during pregnancy, but congenital cases of syphilis will be discussed in a subsequent section. Syphilis is most common in low income economies, particularly in the African continent.²²

Syphilis is divided into early syphilis and late syphilis for the purpose of treatment guidelines. Treatment of syphilis requires the *T. pallidum* bacterium to be exposed to treponemical levels of antibiotics for 7–10 days in early

syphilis and for longer in late syphilis.²³ The development of penicillin in 1940 provided the first practical treponemical antibiotic. Widespread use of penicillin prompted a precipitous drop in cases in developed countries with access to the new drug.²⁴ Penicillin levels of greater than 0.018 mg/L are sufficient for treponemical activity. Development of BPG made it possible to achieve these levels with a single 2.4 million IU injection.²⁵

All major clinical guidelines continue to recommend BPG as the first line treatment for syphilis. Adult treatment recommendations are summarised in Table 5. Clinical guidelines recommend that children are treated with smaller doses of BPG calculated by weight.

There have been some studies exploring the role of oral, non-penicillin antibiotics in treating syphilis. These have not yet been adopted as first line therapy because of technical difficulties, including resistance (azithromycin²⁷) and limited tissue penetration (erythromycin²⁸).

Syphilis in pregnant women

Syphilis infection during pregnancy is common. Worldwide, two million women each year test seropositive for syphilis while pregnant, a variable proportion have active infection. Without treatment, 25% of pregnancies during active infection will end in pregnancy loss or stillbirth.²⁸ Most of the surviving babies will become infected *in utero* with syphilis, reflecting mother-to-child transmission. Babies with congenital syphilis infections may suffer from significant abnormalities of solid organs, skin, joints and cartilage. The irreversible and lifelong consequences of congenital syphilis are entirely preventable. Antibiotic treatment of pregnant women who are seropositive for syphilis prevents transmission to unborn babies. Testing pregnant women for syphilis and treating them is safe, cost-effective and prevents devastating disease outcomes for families.²⁸ The only proven effective antibiotic for preventing congenital syphilis is BPG.

In 2007 the WHO identified syphilis as a feasible target for global elimination, describing it as ‘relatively simple to eliminate and it is inexpensive to detect and treat, making it a possible “easy win” in terms of cost, feasibility and speed of scale-up’.²⁹ In practice, supporting health systems in endemic countries to test pregnant women for syphilis and deliver appropriate BPG therapy has been challenging.³⁰ Facilitating access to antenatal care, screening blood tests, reporting of blood test results and delivery of BPG therapy requires robust health systems to deliver a complex sequence of events.³¹ Shortages of BPG further complicate plans to eliminate congenital syphilis, even when the drug is appropriately prioritised for this indication. The WHO continues to prioritise elimination of congenital syphilis and has developed a late stage draft Health Sector Strategy on sexually transmitted infections (2016–2021). In particular, the WHO calls for action to ‘screen all pregnant women for syphilis, and ensure that those who are seropositive receive appropriate injectable penicillin therapy’.³² Access to BPG underpins these efforts, making it a clear priority for global health.

Table 5: Clinical stages of syphilis and recommended first line therapy in adult patients					
Disease stage			WHO Guidelines 2004 ²³	European Guidelines 2014 ²⁵	Centers for Disease Control and Prevention Guidelines 2015 ²⁶
Early syphilis More infectious, better response to treatment	Primary syphilis	Ulcer (chancre) at the site of infection	Single dose of 2.4 million IU of BPG injected intramuscularly	Single dose of 2.4 million IU of BPG injected intramuscularly	Single dose of 2.4 million IU of BPG injected intramuscularly
	Secondary syphilis	Skin rash, skin and membrane lesions, lymphadenopathy and condylomata	(or procaine benzylpenicillin 1.2 million IU daily for 10 consecutive days)	(or procaine benzylpenicillin 0.6 million IU daily for 10–14 consecutive days ‘i.e. if BPG is not available’)	
	Early latent syphilis	Asymptomatic infection < 2 years of duration*			
Late syphilis Less infectious, lower response to treatment	Latent syphilis	Asymptomatic infection > 2 years duration*	2.4 million IU of BPG once a week for 3 weeks injected intramuscularly (or procaine benzylpenicillin 1.2 million IU daily for 20 consecutive days)	2.4 million IU of BPG injected intramuscularly each week on day 1, 8 and 15 (or procaine benzylpenicillin 0.6 million IU daily for 17–21 consecutive days ‘i.e. if BPG is not available’) ²⁵	BPG 7.2 million IU total, administered as 3 doses of 2.4 million units intramuscularly each at 1 week intervals
	Tertiary syphilis	Gummatous syphilis Late neurosyphilis Cardiovascular syphilis	High dose intravenous penicillin regimens	High dose intravenous penicillin regimens	High dose intravenous penicillin regimens

*<1 year duration in European syphilis guidelines



Congenital syphilis in neonates

Congenital syphilis occurs in babies born to infected but untreated mothers. Congenital syphilis may be detected early (less than 2 years of age) or late (more than 2 years of age). The WHO recommends that all babies born to syphilis seropositive mothers receive a dose of BPG at birth (50,000 IU/kg), irrespective of mother's treatment status.²³ Babies should be followed for the development of symptoms and with tests for syphilis infection. Those with clinical indication of infection should receive a longer course of penicillin-based antibiotics.

Yaws and other Treponemal diseases

Yaws is caused by a chronic infection with a Gram negative spiral-shaped bacterium (*Treponema pallidum*, subspecies *pertenue*). Unlike venereal syphilis (*Treponema pallidum* subspecies *pallidum*), yaws affects the skin and joints. Yaws is the most common non-venereal *treponematoses*, with the other types being bejel (*Treponema pallidum* subspecies *endemicum*) and pinta (*Treponema carateum*).³³

Yaws primarily affects children. 75% of people affected are children less than 15 years old, and the peak incidence occurs between 6 and 10 years of age.³⁴ Transmission is usually via non-sexual skin-to-skin contact.³⁵ Like venereal syphilis, there is a primary, secondary and tertiary phase of infection. Primary infection results in a single skin lesion (the mother yaw) at the point of entry of the bacteria, which resolves within 3–6 months. The secondary phase occurs between a few weeks to two years after the primary lesion, and results in multiple smaller papillomatous or discoid skin lesions, plus bony involvement. The tertiary phase results in non-infectious bony destructive lesions.

Yaws was the first disease targeted for global eradication in 1948 by the newly formed WHO.³⁶ Like other endemic treponematoses, yaws is exquisitely sensitive to penicillin. After the discovery of penicillin, worldwide cases of yaws decreased from 50 million in 1952 to 2.5 million cases in 1964,³⁶ largely due to mass treatment campaigns led by the WHO and United Nations Children's Emergency Fund (UNICEF). Yaws has been successfully eradicated in countries such as India,³⁷ however it is still endemic today in some low income tropical-climate countries in Africa, Southeast Asia, Latin America and the Pacific.³⁴ Yaws is one of the 17 neglected tropical diseases targeted by the WHO for eradication by 2020.³⁸

A recent study has demonstrated that single dose of oral azithromycin is as effective as BPG in treating yaws,³⁹ prompting the WHO to establish the Morges Strategy in 2012.⁴⁰ This strategy involves mass administration of a single dose of oral azithromycin to entire high risk communities. The program has been shown to be effective in treating active cases and also reducing seropositivity, and therefore the prevalence of latent yaws.⁴¹

Treatment doses of medications for yaws include a single dose of oral azithromycin (30 mg/kg up to 2 g) or a single dose of benzathine penicillin (1.2 million IU for adults, 0.6 million IU for children).³⁴ Azithromycin has become the preferred treatment option, but penicillin still has an important role to play for those who are pregnant, allergic to macrolide antibiotics, where an azithromycin is unavailable,³⁴ or where resistance to macrolides is suspected or proven.

Treatment of group A streptococcal pharyngitis to prevent rheumatic fever

Streptococcus pyogenes (group A streptococcus (GAS)) is a global human pathogen associated with a range of superficial, invasive and post-infectious complications. One of the most common GAS infections is pharyngitis or 'strep throat'. Annually, an estimated 616 million people suffer GAS pharyngitis worldwide.⁴² GAS pharyngitis is most common in children 5–15 years (and is responsible for 20–30% of sore throat presentations), although the infection can occur in adults (and may be responsible for 5–15% of sore throat presentations).⁴³ In some parts of the world, GAS pharyngitis is seasonal, with peak incidence in winter and spring. Gold standard diagnosis is by microscopy and culture of throat swabs. Rapid antigen detection tests are available and in some settings clinical scoring tools are used. The throat pain and systemic malaise of GAS pharyngitis is generally self-limiting and resolves without treatment over a period of days.⁴³ A very small number of people experience infective (suppurative) complications including peritonsillar abscess or cervical lymphadenitis. A small number of people with GAS pharyngitis experience non-suppurative, immune mediated, complications.

The most significant post-infectious complication of GAS infection is rheumatic fever (RF). RF is an abnormal immune reaction to GAS infection, occurring up to three weeks after infection. RF classically manifests with fevers, joint pain, and variable involvement of the skin, neurologic and cardiac systems. Poorly understood immune factors mean that young people aged 5–20 years are at greatest risk of RF.⁴⁴ A triad of bacterial, genetic and environmental factors are thought to influence an individual's risk of RF. Socioeconomic factors, including household crowding, sanitation and access to health care, are the predominant determinants of risk. Overwhelmingly, people who develop RF live in developing countries or in vulnerable Indigenous communities of high income countries.⁴⁵ Worldwide, an estimated 471,000 cases of RF occur each year.⁴²

Although symptoms of RF usually resolve spontaneously over weeks, damage to the valves of the heart can persist and progress to rheumatic heart disease (RHD). RHD is a significant cause of cardiovascular morbidity and mortality in developing countries. RF, and subsequent RHD, can be prevented by treating GAS pharyngitis, a strategy known as primary prevention.




Image credit: CDC
Photomicrograph of *Streptococcus pyogenes*. In short chains from pus. Pappenheim's stain 900x.

A 2005 meta-analysis found that antibiotic treatment of GAS sore throat reduced the attack rate of RF by 70%. Use of intramuscular BPG to treat GAS pharyngitis reduced the attack rate by 80%.⁴⁶ A subsequent Cochrane review also found that antibiotic treatment of sore throat significantly reduced the risk of RF (Relative Risk [RR] 0.27; 95% Confidence Interval [CI] 0.21 to 0.60).⁴⁷ In developed settings where the background risk of RF is low, antibiotic treatment of GAS pharyngitis is generally not indicated.^{48,49} However, in high risk populations where RF remains endemic, primary prevention is a key strategy to prevent the development of new cases of RHD in children presenting with sore throat.⁴⁸ There are effective oral regimens for primary prevention (Penicillin V or amoxicillin for 10 days). However, in vulnerable communities with a high burden of RF, adherence to a 10 day course of antibiotics is often limited. In high risk populations when adherence to therapy is challenging, BPG is the preferred antibiotic for primary prevention of RF.⁵⁰

Prophylaxis against recurrent rheumatic fever

Young people who have had one episode of RF are at increased risk of recurrent RF following GAS infection. Without intervention, an estimated 50–75% of young people have recurrent episodes of RF, the majority within 5 years of their initial episode.⁵¹ Repeated GAS infections and recurrences of RF accelerate heart valve damage and the development of RHD. RHD causes heart failure and increases the risk of stroke, infective endocarditis, atrial fibrillation and maternal compromise during delivery. The Global Burden of Disease study estimates that 33 million people live with RHD worldwide and that 275,000 die from the disease each year.⁵²⁻⁵⁴

Secondary prophylaxis is the delivery of regular antibiotics to young people with a high risk of RF recurrence, i.e. those with a history of RF or with established RHD. Prophylaxis prevents RF recurrences and the immune reactions which would otherwise accelerate progression to RHD.⁵⁵ Secondary prophylaxis is the only disease-altering therapy for RHD and is cost-effective.⁵⁶

BPG has been the first line antibiotic for secondary prophylaxis of RF since 1955.⁵⁷ Regular intramuscular injections of BPG reduce the risk of RF recurrence by 87–96%⁵⁸ and are therefore recommended in all major clinical guidelines (Table 6). The dose interval for these

injections is contentious. It has been widely accepted that protection against GAS infection requires a plasma level of BPG to be maintained above the minimum inhibitory concentration (MIC) for GAS (0.02 µg/ml) for three to four weeks after a single intramuscular dose of BPG. The pharmacokinetic profile of BPG is such that soon after administration, a peak in serum penicillin G level is observed, which declines rapidly to drop below 0.01 µg/ml by day 21 post-injection.^{12,59} Plasma penicillin levels have also been shown to drop rapidly below the MIC of GAS within 2.5 weeks post-dosing, often much sooner.¹² Clinical studies suggest that more frequent dosing (2 weekly) provides better protection than less frequent (4 weekly) dosing.⁶⁰ However, in endemic settings with reliable access to high quality formulations of BPG, 4 weekly dosing appears to provide sufficient protection from recurrences.⁶¹ Twenty one or twenty eight day dosing is most commonly recommended in global guidelines (Table 6).

The recommended duration of secondary prophylaxis depends on the clinical picture, age of the patient, ongoing GAS exposure and the risks associated with disease recurrence. Most guidelines recommend regular BPG injections for at least a decade following an episode of clinically significant RF.



Table 6: Recommended protocols for secondary prophylaxis of RF#

Guidelines	Preferred antibiotic	IM BPG doses	Interval of BPG injections	Oral alternatives	Duration
WHO (2001) ⁶²	BPG	<30 kg: 0.6 million IU ≥30 kg: 1.2 million IU	21 days if high risk 28 days if low risk	Phenoxymethyl-penicillin 250 mg twice daily	No evidence of carditis: 5 years since last attack or 18 years old* Resolved carditis: 10 years since last attack or 25 years old Moderate-severe or surgery: lifelong
United States (2009) ⁶³	BPG	≤27 kg: 0.6 million IU >27 kg: 1.2 million IU	4 weeks (3 weeks for selected groups)	Phenoxymethyl-penicillin 250 mg twice daily	For patients with persistent valvular disease, prophylaxis is recommended for 10 years after the last episode of RF or until 40 years of age*
Australia and New Zealand (2012) ⁵⁰	BPG	<20 kg: 0.6 million IU ≥20 kg: 1.2 million IU	4 weeks (3 weeks for selected groups)	Phenoxymethyl-penicillin 250 mg twice daily	No evidence of carditis: 10 years since last attack or 21 years old* No RHD or mild: 10 years since last attack or 21 years old* Moderate: Until 35 years old Severe: 40 years or longer
India (2008) ⁶⁴	BPG	<27 kg: 0.6 million IU ≥27 kg: 1.2 million IU	<27 kg: 15 days ≥27 kg: 21 days	Phenoxymethyl-penicillin Children: 250 mg twice daily Adults: 500 mg twice daily	No evidence of carditis: 5 years since last attack or 18 years old* Mild-moderate: 10 years since last attack or 25 years old Severe RHD or post intervention: lifelong or until 40 years of age
South Africa (1997) ⁶⁵	BPG	<30 kg 0.6–0.9 million IU ≥30kg: 1.2 million IU	3 weekly	Phenoxymethyl-penicillin <30 kg: 125 mg twice daily ≥30 kg 250 mg twice daily	No evidence of carditis: 5 years since last attack or 18 years* Resolved carditis: 10 years since last attack or 25 years old Severe/post valve surgery: lifelong

table adapted from Zühlke L, et al (2013)⁶⁶

* whichever is longer

IM intramuscular

In low resource settings where RHD is endemic it is enormously challenging to deliver regular injections of BPG to children and adolescents for a decade.⁵¹ Substantial efforts to strengthen RHD control activities and to improve secondary prophylaxis have occurred in recent years, including the formation of the global RHD Action movement,⁶⁷ development of the Tools for Implementing RHD Control Programs (TIPs) resource,⁶⁸ publication of an eRegister to document people living with RHD,⁶⁹ development of Needs Assessment Tool (in press) and Roadmap for RHD control (in press). As these resources and activities have impact over the next few years, capacity to deliver prophylaxis, and therefore demand for BPG, is expected to grow. Similarly, the trend towards increasingly robust echocardiographic screening studies for RHD is expected to

continue.⁷⁰ These studies will provide new information about disease which is currently undiagnosed and unmanaged.

The growth in practical resources for RHD control is matched by increasingly strong political and scientific momentum. The African Union has demonstrated critical leadership through a 2015 communiqué identifying seven key actions to eradicate RHD in Africa.^{71,72} The communiqué calls on international stakeholders such as WHO, UNICEF and World Heart Federation (WHF) to ‘address the urgent but neglected issue of the supply of benzathine penicillin G, to ensure that all countries have access to a stable supply of high quality product at all times’.⁷¹ This echoes calls from the WHF to prioritise access to BPG as one of five key targets for RHD control.⁷³

Treatment of skin sores and impetigo

Impetigo, (also known as skin sores or pyoderma) are contagious bacterial skin infections almost always resulting from GAS infection and often coexisting with *Staphylococcus aureus* bacteria. The infection cause skin lesions which subsequently form crusts. These open sores can be painful, persistent and create a risk of developing non-suppurative autoimmune complications of GAS infection, particularly post streptococcal glomerulonephritis and possibly RF, although the latter is not proven.⁷⁴

In 2005 the global prevalence of impetigo was estimated at 111 million children from developing countries.⁷⁵ More comprehensive and recent estimates suggest that 162 million children in developing countries have impetigo at any one time.⁷⁶ Skin sores are most common in low resource settings and in vulnerable communities in high resource countries. Regionally, the highest burden of disease occurs in Oceania. In endemic settings, morbidity from skin sores can be significant; one study from remote Aboriginal communities in Australia showed that 69% of children presented to a primary health care provider for treatment of skin sores by the age of 2 years.⁷⁷ Sores are highly contagious, particularly in settings of overcrowding and limited hygiene facilities. Hot, humid weather and other skin trauma (scabies, fungal infections, insect bites) also increases the risk of skin sores.

Treatment of skin sores requires antibiotics, and a wide range of topical and systemic antibiotics have been used for this purpose.⁷⁸ A large number of studies have been conducted to identify the optimum management of skin sores. A 2012 Cochrane review suggests that topical antibiotics or non-penicillin oral antibiotics are the most appropriate first line therapy.⁷⁸ However, this review included only a single study from highly endemic, low resource settings.⁷⁶ In regions of very high prevalence, a single, weight-based dose of BPG is considered first line therapy for skin sore treatment.⁷⁹ New research shows that short course oral co-trimoxazole is a suitable alternative to BPG.⁷⁹ However, BPG remains an important treatment option for skin sores in endemic areas where adherence to therapy may be challenging.



Image credit: CDC
This child presented with these maculopapular lesions that proved to be impetigo.




Image credit: CDC / Dr. Thomas F. Sellers
The lesions of this patient's forehead proved to be impetigo, usually caused by *Staphylococcus aureus* bacteria, and sometimes Group A *Streptococcus* sp. bacteria are responsible.

Prophylaxis against infection in hyposplenism and asplenia

The spleen is a solid, intra-abdominal organ that filters red blood cells and contributes to immune protection against polysaccharide encapsulated bacteria, particularly *Streptococcus pneumoniae*, *Neisseria meningitidis* and *Haemophilus influenzae*. The spleen can be damaged by disease or injury. Without a functional spleen, immune mechanisms are impaired and the risk of sepsis from encapsulated microorganisms increases significantly. Mortality from overwhelming infection in these patients approaches 50%.⁸⁰ Antibiotic prophylaxis is generally recommended to reduce this risk, although high quality clinical trial data supporting prophylaxis is limited.⁸¹

The risk of serious infection from encapsulated organisms is greatest following surgical removal of the spleen (splenectomy). Typically, this occurs following trauma or spontaneous major bleeding from the spleen. Many guidelines recommend twice daily oral antibiotic prophylaxis for two years following splenectomy; longer if patients have other risk factors for infection.⁸² Many post-splenectomy patients prematurely discontinue their antibiotic prophylaxis, sometimes with devastating outcomes.⁸³ An estimated 50,000 asplenic people live in the United Kingdom and would benefit from improved secondary prophylaxis against life-threatening infection.⁸⁰

Another relatively common global cause of reduced spleen function is sickle cell disease. Sickle cell disease is an inherited disorder of haemoglobin synthesis which causes red blood cells to deform into a sickle shape at low oxygen levels. The genetic mutations that cause sickle cell disease are most common in Sub-Saharan Africa, equatorial Africa, Mediterranean Basin and Saudi Arabia.

Abnormal sickle-shaped red blood cells accumulate in the spleen and cause irreversible damage. By the age of 5 years, 95% of children with sickle cell disease have a severely damaged spleen (functional asplenia).⁸⁴ Children with functional asplenia following sickle cell disease are at high risk of severe infection. In the pre-penicillin era these infections were often fatal. In the 1980s, a randomised controlled trial providing oral penicillin prophylaxis to children with sickle cell disease demonstrated an 85% reduction in the incidence of infection ($p = 0.0025$) and a reduction in deaths from infection.⁸⁵ Subsequent studies have confirmed the protective effect of prophylactic penicillin for young children with sickle cell disease.⁸⁶ Advances in vaccines against *Str. pneumonia* and *H. influenzae* Type B have contributed to reduced mortality in young people with sickle cell disease. Various institutions have provided guidance on the form and duration of penicillin prophylaxis, outlined in Table 7.

Table 7: Antibiotic prophylaxis recommendations for asplenia, hyposplenism and sickle cell disease		
Update of guideline for the prevention and treatment of infection in patients with an absent or dysfunctional spleen	British Committee for Standards in Haematology Britain (2002) ⁸⁷	Lifelong prophylactic antibiotics are still recommended (oral phenoxymethyl-penicillin or erythromycin)
Evidence-based management of sickle cell disease	National Institute of Health, United States (2014) ⁸⁸	Administer oral penicillin prophylaxis (125 mg for age < 3 years and 250 mg for age ≥ 3 years) twice daily until age 5 years in all children with HbSS*
Recommendations for the management of sickle cell disease in South Africa	Expert consensus status South Africa (2014) ⁸⁹	'There is debate on the prophylactic use of oral antibiotics in all patients with sickle cell disease. However, penicillin VK 125 mg twice daily orally for children under 3 years of age and 250 mg twice daily for children older than 3 years of age is recommended, and continued until adolescence. Erythromycin is recommended for patients who are allergic to penicillin'

*HbSS is the most severe form of sickle cell disease

Absolute adherence with the secondary prophylaxis regimen appears critical to life saving outcomes. Missing even a single dose of antibiotic is associated with an increased risk of severe infection.^{90,91} Twice daily antibiotic administration is challenging in young children, even in developed settings.⁹² In low resource settings with a high burden of sickle cell disease, adherence may be even more difficult. Compliance may be further compromised by limited access to affordable paediatric suspensions of oral penicillin V. In addition, once the powdered suspension is mixed with liquid the product has a shelf life of only 14 days.⁹³ Some have suggested that regular intramuscular injections of BPG are a reasonable alternative to twice daily oral medication. This approach was used with encouraging results in a long term program in Jamaica.⁹⁴ Current formulations of BPG are unlikely to be acceptable or available for large scale prophylaxis of infection in asplenic patients. However, reformulation to reduce pain and increase dose interval could provide a novel opportunity to improve adherence. A more suitable formulation may reduce the costs associated with preventable morbidity and mortality from sepsis.

Prophylaxis against recurrent cellulitis

Cellulitis is an infection of the skin and subcutaneous tissue. Infections are typically caused by GAS, *S. aureus* and some other streptococcal species. Extremities, particularly the lower limbs are most commonly affected. After a first episode of cellulitis, 15–30% of people will have recurrent infections.^{95,96} Risk factors for recurrent cellulitis appear to be local factors (skin disruption, fungal foot infections, leg surgery, oedema, and deep vein thrombosis) and a weaker effect of systemic factors (potentially including body mass index, smoking, and systemic causes of peripheral oedema). Diabetes has been considered a risk factor but evidence for this is weak. The global burden of cellulitis and recurrent cellulitis is high.⁹⁷

Table 8: Guidelines on first line antibiotic prophylaxis to prevent recurrent cellulitis		
Infectious Diseases Society of America ¹⁰⁰	United States 2014	'Administration of prophylactic antibiotics, such as oral penicillin or erythromycin twice daily for 4–52 weeks, or intramuscular benzathine penicillin every 2–4 weeks, should be considered in patients who have 3–4 episodes of cellulitis per year despite attempts to treat or control predisposing factors (weak, moderate)'

Morbidity from acute cellulitis is substantial; each episode necessitates antibiotic treatment and may require hospital admission. Given the burden of recurrent disease, researchers have been exploring opportunities for antibiotic prophylaxis. A 2014 Cochrane meta-analysis of five studies identified that antibiotic prophylaxis is beneficial for reducing recurrent episodes of cellulitis (RR 0.46, 95% CI 0.26–0.79).⁹⁶ Only one study included in the Cochrane review used BPG for prophylaxis and results from that individual study were not statistically significant.⁹⁸ Economic analysis (based on oral prophylaxis) suggests that prevention of recurrent cellulitis is cost-effective.⁹⁹

Overall, the majority of evidence suggests that penicillin prophylaxis against recurrent cellulitis is likely to be effective. Current recommendations are outlined in Table 8.

A formulation of BPG, which could provide protective serum penicillin levels without the need for daily antibiotics may be more acceptable to patients, improve adherence and maximise clinical benefit. In high resource settings, where recurrent cellulitis is most amenable to prophylaxis, a sustainable BPG market may be possible.

Lyme disease

Lyme disease is caused by the *Borrelia burgdorferi* bacterium and is acquired by humans following the bite of an infected blacklegged tick. The disease manifests with fatigue, rash and joint and nervous system impairments. Diagnosis and treatment of Lyme disease is the subject of ongoing research and some controversy.¹⁰¹ Some guidelines recommend the use of BPG to treat the causative infection, but the overall role of the antibiotic remains unclear.

SHORTAGES OF BPG

Overview	20
Australia	20
Brazil	21
China	21
India	22
South Africa	22
Timor-Leste	23
North America	23
Market vulnerabilities of BPG	24
Limited number of manufacturers for the active pharmaceutical ingredient	24
Poor visibility of demand	25
Overly aggressive price reduction practices in procurement	25
Fragmented and low volume markets	26
Business decisions by manufacturers	26



OVERVIEW

BPG has been subject to global stock outs over the last decade in both high and low resource settings.

The fragmented melee of manufactures, suppliers and procurement agencies has complicated attempts to describe the sources of drug or the scale of shortages. Irrespective of cause, it is clear that global shortages have had significant worldwide impact on countries and procurement agencies trying to purchase BPG.

Persistent anecdotal reports of BPG stock outs leading to disruption of secondary prophylaxis for RF were explored by the WHF in 2011. In a survey of 39 cardiologists in Asia-Pacific, Africa, Central and South America, almost all reported 'minimal' access to BPG and 35% reported inadequate supply to treat patients according to a recommended schedule of secondary prophylaxis injections.^{102,103} At a global meeting in Geneva in December 2015, three United Nations procurement agencies reported chronic shortages of BPG.¹⁰⁴ This correlates with reports of shortages discussed by UNICEF representatives at the launch of RHD Action in New York, September 29th 2015.

Media and professional reports suggest that multiple drug shortages have occurred globally over at least the last 15 years, including Nepal (2003),¹⁰⁵ New Zealand (2007),¹⁰³ France (2013),¹⁰⁶ Indonesia (2013),¹⁰⁷ Poland (2014),¹⁰⁸ and Egypt (2015).¹⁰⁹

In a small number of countries, it has been possible to collect more detailed information; these case studies are presented in this report. However, the most vulnerable countries with the greatest need for BPG are likely to be unrepresented.

Australia

Australia does not have a formal list of essential medicines. Instead, clinical guidelines indicate that a single or short course of BPG injections is recommended for management of syphilis, skin sores and pharyngitis.¹¹⁰ An extended course of BPG is indicated for secondary prophylaxis against recurrent RF.⁵⁰

BPG is subsidised by the Australian government through the Pharmaceutical Benefits Scheme (PBS) for most patients. As of April 2016, the maximum cost to the patient for *Bicillin L-A* (Pfizer) is AU\$38.30.¹¹¹ Indigenous Aboriginal and Torres Strait Islander Australians living in remote areas are able to access the drug at health clinics without cost.¹¹²

There have been five periods of BPG shortage in Australia in the 20 years from 1995–2015.¹¹³ Two of these shortages, in 2001 and 2014, resulted in only minimal disruption of services, while a prolonged shortage from 2006 to 2008 threatened to disrupt treatment protocols.¹¹⁴ The 2006–2008 shortage of BPG was reportedly caused by changes to the manufacturing practices by the single BPG manufacturer used in Australia and subsequent delays in regulatory submissions.¹¹⁵ A powdered formulation of BPG was introduced during this period to ensure supply, but resulted in widespread concerns about the acceptability, prescription and administration of the drug.¹¹⁶ *Bicillin L-A*, produced by Pfizer, was re-introduced to Australia in 2008.¹¹⁷ Subsequent shortages in 2012¹¹³ and 2014¹¹⁸ have been mitigated by careful management of the drug at pharmacy level but have raised ongoing concerns about reliance on a formulation produced by a single manufacturer in a single plant.¹¹³

Brazil

In Brazil, BPG (called benzilpenicilina benzatina) is included in the 2010 National Essential Medicines list (Relação Nacional de Medicamentos Essenciais) in 0.6 million and 1.2 million IU doses.¹¹⁹ Brand names used in Brazil have included two local products: *Benzetacil* (Eurofarma, Brazil) and *Bepeben* (Teuto Laboratory, Brazil), and an earlier product *Penicilina G Benzatina* (Ariston, India). Formulation of the major *Benzetacil* product occurs in Brazil with active pharmaceutical ingredient (API) sourced from international third parties. In Brazil, nursing staff have been so concerned about the risks of adverse reactions when administering BPG in primary care settings the practice has previously been restricted by the nursing council.¹²⁰ In 2015, given the increasing burden of congenital syphilis, a special resolution was passed allowing community administration of BPG.¹²¹

BPG in Brazil is usually free at point of care through the health care system. BPG can also be purchased directly from pharmacies for approximately 10 reais (US\$2.5).

Shortages of BPG in Brazil reached critical levels in 2015 when widespread stock outs limited access to treatment of syphilis and RF.¹²² Shortages were primarily associated with reduced global access to API. A special hearing of the Social Security and Family Commission was convened on September 29th 2015, including public health officials and pharmaceutical industry representatives.¹²³ Following this meeting, a committee was formed to establish strategies for improving BPG supply. Doctors in Brazil are awaiting updates on the activities and outcomes of this committee.

Prior to contemporary stock outs, access to BPG was reasonable by global standards. A 2001 review of access to essential medicines in Minas Gerais state was conducted by Management Sciences for Health.¹²⁴ The study revealed that BPG was available in some public medical stores (50%) and public health facilities (43%). Stock of BPG was greater in charitable institutions (69%), private facilities (71%) and private pharmacies (90%).

Despite these challenges, the Brazilian national health system *Sistema Único de Saúde* (SUS) uses a human rights approach to health which supports universal access to primary health care.¹²⁵

China

In China, BPG (called 苄星青霉素) is included on the national Essential Drugs List and on provincial lists. The China Food and Drug Administration (CFDA) lists three doses of BPG in 0.3 million, 0.6 million and 1.2 million IU increments. A number of local manufacturers are identified by the CFDA.¹²⁶

The price of BPG in China is determined by the government and covered by the health care reimbursement scheme, intended to cover all medications on the Essential Drugs List.^{127,128} In July 2011, the maximum retail price of BPG was set at 9 Chinese yuan (CHY) for 1.2 million IU dose (US\$1.39). Additionally, informal sources of information for clinicians in China¹²⁹ suggest the retail price of BPG from one manufacturer ranges from CHY 2.28 to 9.5 (for 1.2 million IU dose, equivalent to US\$0.24–1.39) for providers in 7 locations across the country.¹³⁰

There is limited formal information on supply, availability and quality of BPG in China. However media reports, including accounts reported in Chinese Government administered publications online suggest that stock outs occur, consistent with international experience.^{131,132}



Image credit: National Yaws Control Programme, Ghana.
Health care worker preparing benzathine penicillin in a yaws treatment campaign, West Akim district, Ghana.

India

In India, BPG (referred to as benzyl benzathine penicillin) is included in the most recent 2011 edition of the National List of Essential Medicines of India in 0.6 million IU and 1.2 million IU doses.¹³³ The earlier 2003 edition had also included 2.4 million IU doses.¹³⁴ BPG also appears on the National Formulary of India, indicated for 'mild to moderate infections of upper respiratory tract due to susceptible streptococci, syphilis, prophylaxis of rheumatic fever'.¹³⁵

Anecdotal reports of poorly characterised adverse reactions are common in India prompting concern about the quality and safety of BPG products. In India, skin testing for allergy is recommended before doses of BPG.¹³⁵ Concerns about adverse reactions have reportedly prompted restrictions on the use of BPG in some states, including Kerala and Tamil Nadu, sometimes extending to outright bans on BPG administration.¹³⁶

The price of BPG in India is determined by the government of India and the National Pharmaceutical Pricing Authority. In 2007, the price of a 1.2 million IU vial of BPG was set at 13.08 rupees (US\$0.20).¹³⁷

South Africa

BPG is an essential medicine in South Africa and is listed in the national formulary for the treatment of RHD, prevention of recurrent RF, and syphilis.¹³⁸ The government of South Africa supports medication transparency through its South African Medicine Price Registry website.¹³⁹ As of April 2016, the site indicates that two doses of BPG (1.2 million IU and 2.4 million IU) are registered for use by the South African Medicines Control Council from three manufacturers: Biotech Laboratories, Caps Pharmaceuticals and Fresenius Kabi South Africa. Cost of medication is usually borne by patients/families and costs range from R4.31 to R26.09 (US\$0.35–2.09) per single dose of 2.4 million IU and R6.36 to R26.62 for 1.2 million IU (US\$0.34–2.13); however financial assistance, dependent on the patient's resources and age, is generally available at public health facilities.

In 2015 South Africa was struck by significant shortages of BPG, affecting both 1.2 million IU and 2.4 million IU doses. The shortages were attributed to stock outs of API necessary for drug manufacture. The National Department of Health was forced to investigate use of a Section 21 application to secure emergency supplies through an import license. Supply has been stable to date in 2016.^{140,141}

A national essential medicines consortium, the Stop Stock Outs Project,¹⁴² has been launched by Médecins Sans Frontières, Rural Doctors Association of SA, SA HIV Clinician's Society, SECTION27 (Rural Health Advocacy Project) and the Treatment Action Campaign. Stop Stock Outs provides multiple platforms (mobile, SMS, What's App and email) for clinicians and patients to report stock outs from their local areas. All verifiable reports are 'escalated up to the supply chain, and resolution is sought through the engagement of civil society with accountable government individuals and entities'.¹⁴²

Timor-Leste

The 2010 'Essential Medicines List for Timor-Leste' includes two dose sizes of BPG under a 'vital' designation.¹⁴³ BPG is intended to be available at all levels of the health system (Level 1 District Health Posts, Sub-District Level Health Centres, District Level Health Centres and at referral hospitals). BPG is needed in Timor-Leste for the treatment of syphilis and prophylaxis of RF.

In Dili, the country's capital, physicians and paediatricians at the Hospital Nacional Guido Valadares frequently diagnose cases of severe RHD. BPG is usually available within the hospital, but stock outs have occurred. On discharge, children with RHD are advised to attend their local community health centre to receive monthly BPG injections.

One prominent non-government organisation (NGO) healthcare institution in Timor-Leste is the Bairo Pite Clinic, based in Dili. The clinic has a small registry of people living with RHD, who attend the clinic regularly for BPG injections for secondary prophylaxis, although national stock outs of BPG have compromised the program at times.

BPG available in Timor-Leste appears to be an Indonesian product *Benzatil Benzil Penisilin* (Phapros Pharmaceuticals). This product is manufactured in Indonesia, and there is understood to be a reasonable supply of this drug at National Hospital Pharmacy via the national procurement agency Serviço Autónomo de Medicamentos e Equipamentos de Saúde (SAMES).

North America

Shortages of BPG also periodically occur in the United States and Canada, most recently in 2002¹⁴⁴ and in 2006.¹¹⁵ In April 2016, Pfizer notified the Food and Drug Administration (FDA) that all three dose sizes of *Bicillin L-A* were 'currently in shortage' because of manufacturing delays. Backorder is expected to resolve by July 2016.¹⁴⁵ This shortage prompted advice from the Public Health Agency of Canada to restrict the use of *Bicillin L-A* to specific indications, noting that these 'may differ from the preferred and alternative treatment recommendations in the Syphilis chapter of the Canadian Guidelines on Sexually Transmitted Infections'.¹⁴⁶

MARKET VULNERABILITIES OF BPG

Drug shortages are an increasingly well-documented global challenge, affecting both high and low resource settings.¹⁴⁷

Some kinds of drugs are more vulnerable to shortage than others. A recent WHO report identified a number of risk factors for drug shortage: older products, off-patent drugs, difficult to formulate, tight or defined shelf life and few/single manufacturers.^{147,148}

The report also identified that sterile injectables are particularly at risk of drug shortages. Reasons for this vulnerability are identified below, with particular reference to BPG.

Limited number of manufacturers for the active pharmaceutical ingredient

Production of pharmaceutical end-products involves a number of steps, each of which may be undertaken by different companies, outlined in Figure 2. This is certainly the case for BPG where a small number of companies produce API for others who later formulate and package the product.

Information about API manufacturers is generally proprietary, however there are indications that access to Good Manufacturing Practice (GMP)-certified API is challenging.

For example, a number of contemporary stock outs have been attributed to problems with GMP certification of API from a major Chinese supplier. In November 2014, API for BPG produced by the North China Pharmaceutical Group Semiyntech Co. Ltd, was found to be non-compliant with GMP regulations by the French National Agency for Medicines and Health Products Safety.¹⁵¹ The API had been used to develop finished drug product by Phanpharma and subsequently sold to purchasers. These BPG products had been supplied to Ethiopia and Liberia and were subsequently recalled.¹⁵² This was followed by a European Union statement of non-compliance and a WHO statement on the inspection results.¹⁵³ In the Philippines, accreditation of BPG quality was contested in court in 2007 during a contracting dispute.¹⁵⁴ Shortages of buffers and reagents required for formulation of BPG may amplify difficulties accessing API.

The small number of manufacturers in the BPG market is likely to be a persistent challenge. In 2013 the United States FDA issued guidance on reducing product contamination for manufacturing plants producing penicillin and other beta-lactam API and antibiotic formulations.¹⁵⁵ This guidance recommends dedicated production areas including facilities, air handling equipment and processing equipment be reserved for the production of high sensitising materials. The infrastructure required to meet these guidelines is substantial, creating a barrier to new manufacturers entering the market. Decommissioning of penicillin production facilities is also complicated, making it difficult for companies to recoup their infrastructure investment if companies decide to manufacture other product lines.




Figure 2: Schematic overview of pharmaceutical manufacturing process(adapted from figure 1¹⁴⁹ and figure 4-1.¹⁵⁰)

Poor visibility of demand

Global procurement demand for BPG is driven by major indications; syphilis and prophylaxis against RF. These clinical indications have a number of complicating factors:

- Syphilis outbreaks are relatively unpredictable and may produce a sudden increase in demand for BPG products.^{156,157}
- In outbreak and non-outbreak conditions, diagnosing syphilis can be challenging. Diagnosis and treatment requires health infrastructure which can provide, interpret and follow-up on blood tests for individuals at risk, some of whom will not have symptoms. Therefore, demand for BPG is partly a function of health system capacity.
- Demand for BPG for secondary prophylaxis against RF is also a function of diagnostic efforts. The people who benefit most from prophylaxis are asymptomatic and are increasingly identified through echocardiographic screening studies. This means that researchers and RHD screening projects must attempt to procure BPG in advance of identifying cases, often in small volumes and often based on inaccurate estimates of disease burden.

In addition to these issues, clinical indications for BPG are often associated with social stigma or lack strong advocacy platforms for people in need of the drug. In contrast to other drugs used in similar settings (anti-retroviral medications for HIV, medication for tuberculosis) there is relatively little community-lead demand for the product.

Overly aggressive price reduction practices in procurement

The price for BPG is low (Table 9). In some countries the price is fixed by the government, further limiting financial sustainability of the product.¹⁵⁸ This focus on price at the expense of quality may be undermining the BPG market in a way which ultimately undermines access to the product.¹⁴⁷

Table 9: Median prices of BPG in 2014			
Product	Setting	Median price per vial	Price paid by
Benzathine penicillin G 1.2 million IU	Global supplier price average	US\$0.13	Wholesale sales price
	Global national purchaser average	US\$0.22	National purchase price
Benzathine penicillin G 2.4 million IU – buyer prices	Global supplier price average	US\$0.26	Wholesale sales price
	Global supplier price average	US\$0.28	National purchase price

table adapted from Management Sciences for Health, International Drug Price Indicator Guide¹⁵⁹

Fragmented and low volume markets

BPG procurement is plagued by fragmentation across different indications. UN procurement agencies are involved in the BPG market include the United Nations Population Fund and the UNICEF. Even large UN agencies have reported recent difficulties in sourcing BPG.¹⁶⁰ At a national level procurement is much smaller in scale and more difficult. For example, the UN Agency for Palestine Refugees sought expressions of interest to supply 100 vials of 1.2 million IU of BPG, 2015.¹⁶¹

Business decisions by manufacturers

The highest volume indications for BPG (syphilis and secondary prophylaxis against RF) occur in low resource settings where procurement systems, supply chain management and diagnosis are weakest. This means that although there is a clear clinical need for the drug, there is not always a well-developed system for delivery. Erratic supply and demand complicate supply chain management, particularly for multi-dose regimens for prophylaxis. Patients who are unable to access or purchase BPG are less likely to return for subsequent doses, paradoxically reducing demand even when clinical need has been identified and BPG prescribed.

BPG is identified in a report to the World Health Assembly as a sentinel example of a sterile injectable subject to frequent drug shortages.¹⁴⁷ Opportunities identified by WHO to mitigate drug shortages include reporting mechanisms, notification of expected stock outs and identification of a minimum price for products such as BPG which have a limited market.¹⁴⁷ Market shaping opportunities, including minimum price points, are addressed in the Actions and Recommendations section of this report.

CHALLENGES FOR THE SUPPLY AND USE OF BPG

Adverse drug reactions to BPG	28
Systemic adverse reactions	28
Local adverse reactions	29
Quality and behaviour of BPG	31
Duration of action	31
Suitability for suspension	31
High rates of idiosyncratic adverse reactions	31
Antibiotic resistance	32



ADVERSE DRUG REACTIONS TO BPG

The WHO defines an adverse drug reaction (ADR) as a ‘response to a drug that is noxious, unintended or undesired occurring at doses normally used for the prevention, diagnosis or treatment of disease’.¹⁶²

An ADR may be systemic, affecting the whole body, or localised to the site of administration. Systemic and local adverse reactions to BPG are a global concern for clinicians and consumers of the product.

Systemic adverse reactions

Systemic ADRs can be further classified into Type A reactions (pharmacologic, dose related, effects of the drug including side effects, toxicity and drug interactions) and Type B reactions (unpredictable, dose independent, hypersensitivity).¹⁶³ Type B reactions are the predominant concern in the use of beta-lactam antibiotics.¹⁶⁴ These can be considered immunologic or idiosyncratic, where the mechanism of the adverse reaction is poorly understood.¹⁶³

Type B immunologic reactions are caused by an immune response to components of the penicillin molecule.¹⁶⁵ Immediate reactions are generally IgE-mediated and cause anaphylaxis with characteristic hypotension, bronchospasm and angioedema. Late allergic events are IgG-mediated and are associated with cutaneous manifestations and serum-sickness reactions.

Globally, penicillin is considered one of the commonest causes of Type B ADR.^{166,167} Up to 10% of people report a history of penicillin allergy.¹⁶⁸ However, the absolute risk of true anaphylaxis to penicillin in an individual is low. Standard reference books suggest that the prevalence of beta-lactam allergy is 0.05–2%, with anaphylaxis occurring in 1 in 100,000 individuals.^{169,170} A large outpatient study of 3,375,162 patients in the United Kingdom receiving at least one penicillin prescription suggested 0.18% experienced an allergic-like event after their initial penicillin prescription and no death occurred.¹⁷¹

There have been a number of studies quantifying the specific risk of BPG injections, either intentionally or through incidental reports. A 2013 systematic review analysed 12 of these studies (1954–2012), plus one large study of all forms of penicillin prescription.¹⁷² The systematic review authors noted that results were highly heterogeneous across time and geography. However, pooled analysis confirm that the risk of serious adverse reaction from BPG injections is low (Table 10).

The 2013 systematic review confirmed that the risk of an adverse reaction was higher when patients were exposed to BPG on multiple occasions.¹⁷² There have been long-standing concerns about the safety of ongoing doses of BPG for prophylaxis. In 1991, the International Rheumatic Fever Study Group (IRFSG) conducted a large scale, prospective international study to document adverse reactions to BPG, particularly for patients receiving repeated doses of the drug over time.¹⁷³ The IRFSG study included 1,790 patients from 11 different countries who received 32,430 injections of BPG. The drug was sourced from 12 different manufacturers and given to patients aged 5–23 years. This study reported allergic reactions in 57 patients (3.2%), immediate anaphylactic reactions in four patients (0.2%) and one fatality (0.05%, 0.31/10,000 injections) The frequency of anaphylactic reactions was calculated at 1.23 per 10,000 injections.¹⁷⁴

Since the IRFSG study, only two studies have reported on the rates of allergic reaction to BPG for RHD. A 2011 retrospective study in Nepal of 77,000 injections given to 4,700 patients reported 65 patients with allergic reactions (1.4%), five of those being anaphylactic reactions (0.1%). Eight episodes of vasovagal syncope were also reported (0.16%).¹⁷⁵ A 2014 retrospective study in Turkey found suspected allergy in 11 patients (2%), with no anaphylactic reactions.¹⁷⁶ A United States FDA analysis of long term penicillin therapy concluded ‘Although there are no specific studies that directly assess the safety of these antibiotics when given over an extended period of time, there is a significant amount of information that supports the safety of such therapy.’¹⁷⁷

Although rare, fatalities in RHD patients receiving BPG prophylaxis have been reported: in 1958,¹⁷⁸ 1962,¹⁷⁹ 1991,¹⁷⁴ and 2000.¹⁸⁰ The majority of these fatalities have occurred in patients with severe RHD disease manifested as cardiac complications. The presence and nature of any association between severe cardiovascular disease and death associated with BPG injections remains unclear. It is feasible that severe episodes or fatalities, particularly if they occur in patients with severe RHD, may be due to vasovagal episodes rather than a reaction to the injected substance.

Serious systemic reactions from BPG are rare. The risk of adverse reactions is certainly less than the morbidity and mortality associated with syphilis infection, RHD and other indications for BPG. Fear of anaphylaxis should not prevent people with a clear indication for BPG therapy from receiving appropriate treatment. However, anecdotal reports suggest that fear of adverse events prevents health care staff from delivering injections when indicated.¹⁷²

In Nepal, there are reports that health workers have been assaulted or jailed following adverse reactions to BPG.¹⁸¹ In Brazil, nursing staff have been so concerned about the risks of administering BPG in primary care the nursing council limited the practice.¹²⁰ There are unconfirmed reports that BPG has been banned in some states in India (Kerala and Tamil Nadu) because of fear of ADRs.^{182,183} In Zambia, fear of anaphylaxis prevented health care workers adhering to standard treatment guidelines.¹⁸⁴

A public-private partnership is underway in Zambia to eliminate RHD.¹⁸⁵ Partners include the University Teaching Hospital Lusaka, Ministry of Health, Ministry of Education, University of Zambia, University of Cape Town and the pharmaceutical company Novartis.¹⁸⁴ As part of this partnership, a two-day workshop on penicillin allergy was held in 2013. The curriculum was delivered by a visiting professor and based on guidelines from the World Allergy Organization. Twenty nine attendees had demonstrably improved knowledge following the workshop and reported that training would change their clinical practice.¹⁸⁶ Allergy kits have also been developed to be stocked at health clinics which are part of the RHD control program.¹⁸⁴

Local adverse reactions

Local ADRs include effects at the site injection, such as pain and redness.

Intensity of pain

Pain on injection of BPG has been a problem since the product was initially developed. Although anecdotal reports of pain are common, only a small number of studies have used validated sales to quantify the experience of BPG. In a New Zealand study, 405 patients (5 years of age to adult) reported a mean pain score of 5.4/10 during administration of *Bicillin L-A* (Pfizer).¹⁸⁷ In the Middle East, 117 paediatric patients (>10 years) were given injections of powdered BPG diluted in 3.2 ml of sterile water for prophylaxis of RF. The mean score for pain on administration was 6.7/10 (range 4–10).¹⁸⁸

Duration of pain

A number of studies suggest that pain from BPG injection lasts a number of days. In Australia, 30% of 165 children receiving BPG injections for treatment of sores skin reported pain two days after BPG injection and five children required pain relief.¹⁸⁹ A recent Australian case study provided radiologic evidence of myositis following routine BPG injection in a 7 year old boy. Despite uncomplicated administration of the *Bicillin L-A* (Pfizer), the child limped for a number of days after injection.¹⁹⁰

Determinants of pain

The determinants of injection site pain for BPG are unclear. Potential contributors include:

VOLUME OF INJECTION

BPG is routinely administered in volumes between 2–5 ml, but intramuscular (IM) injection of up to 8 ml has been reported. Most users define large volume IM injections as greater than 3 ml.¹⁹¹ A recent study in France provides some information about the tolerability of different volumes of BPG injection. In France, 50 adult patients receiving three doses of BPG for treatment of syphilis received either 2.4 million IU of BPG mixed with 7 ml of saline and 1 ml 1% lignocaine, or two injections of 1.2 million IU of BPG mixed with 3.5 ml of saline and 0.5 ml of 1% lignocaine. Mean pain was 3.1/10 (range 0–8) with the 2.4 million IU dose and 2.7/10 (range 0–7) with two 1.2 million IU doses. The difference between the reported pain scores was not statistically significant ($p = 0.28$). When participants were allowed to choose the dose delivery for their third and final BPG dose they were evenly split between options.

Table 10: Pooled absolute risk of adverse reactions to BPG			
Outcome	Number of patients receiving 1 or more BPG injections	Number of events during observation	Absolute risk % (95% CI)
Death	2,108,117	4	0 (0–0)
Anaphylaxis	2,108,117	54	0.002 (0–0.003%)
Adverse reaction	3,465,322	6,377	0.169% (0.073%–0.257%)

table adapted from Galvao et al (2013)¹⁷²

FORCE OF INJECTION

IM injections should be given slowly, allowing muscle fibres to accommodate the volume of injection.¹⁹² However, the difficulty suspending powdered formulations of BPG means that needles are frequently blocked.^{9,193} This requires staff giving the injection to increase the force applied to the needle stopper, sometimes causing a period of high velocity when the obstruction clears. On some occasions needles are irrevocably blocked and a new injection must be given, which is traumatic for patients and staff and may be associated with inaccurate dosing of product.

INJECTION SITE AND TECHNIQUE

There is an extensive body of nursing literature on IM injections, including optimal positioning, approach and technique.¹⁹² There are few definitive conclusions on best practice, nor a clear indication of how these apply to BPG. It is possible that some local injecting practices may increase pain associated with injection. In Australia, Pfizer has supported the development of a video resource outlining recommended injection technique for the *Bicillin L-A* product.¹⁹⁴

CHEMICAL PROPERTIES OF BPG

It is possible that properties of BPG or excipients cause more injection site pain than other similarly sized injections. Certainly, BPG injections appear to be more painful than 4 ml injections of oil based depot preparations of testosterone.¹⁹⁵ If research indicates that physical properties of BPG contribute to pain then pharmacologic interventions/additives may need to be prioritised as a pain reduction strategy.

Interventions to reduce injection site pain

Pain and fear of pain may be a barrier to adherence, particularly when multiple doses of BPG are required, as in late syphilis and prophylaxis against RF. The evidence for the impact of pain on adherence is variable; pain is not reported as a major determinant in secondary prophylaxis studies from Australia¹⁹⁶ or India,¹⁹⁷ although it is a significant barrier in Uganda.^{198,199}

A number of interventions have been suggested to reduce the pain on IM injection.^{50,200}

ADDITION OF LOCAL ANAESTHETIC

Many authors have suggested adding local anaesthetic to reduce the pain of BPG injections. There is some evidence that this is effective in reducing pain and does not appear to affect serum penicillin concentration.²⁰¹⁻²⁰³ The practice occurs widely: it is recommended in the Syphilis Treatment Guidelines from the United Kingdom (noting that this is an unlicensed indication²⁰⁴) and in the New Zealand guidelines for the 'Preventing Rheumatic Fever' Program.²⁰⁰

VIBRATION, COLD AND RELAXATION

An increasing number of adjunct techniques for managing injection site pain have been explored. In New Zealand, use of a vibrating cold pack has been acceptable to patients (particularly those under 13 years) and is associated with reduced pain and fear.²⁰⁵

QUALITY AND BEHAVIOUR OF BPG

Clinicians routinely express concern about the quality of BPG products available.⁹ These concerns are generally based on observation of drug administration or action: that it is difficult to give BPG, that there are an unexpectedly high number of adverse reactions or that the drug appears to 'fail' in settings where resistance is not expected.

Duration of action

Data from the 1950s suggests the serum concentration of penicillin could be detected above the MIC (generally considered between 0.01–0.03 µg/ml¹²) for GAS three or more weeks after BPG injection.⁸ However, contemporary studies suggest that serum concentration levels fall faster than expected than for earlier studies.

In a population of 164 male military recruits receiving a quality-assured form of BPG (*Bicillin L-A*, Monarch Pharmaceuticals), the mean serum penicillin level fell below 0.02 µg/ml by day 11 post-injection.¹² This finding compares with an earlier study of 86 male military recruits who received a 1.2 million IU dose of BPG (*Bicillin L-A*, Wyeth-Ayerst Laboratories).²⁰⁶ Only 34 participants had detectable serum penicillin on day 7 post-injection (mean = 0.01 µg/ml) and in only three participants by day 14 (mean = 0.016 µg/ml). No penicillin was measurable at day 21 or day 28. In contrast, in a study from Thailand, 20 male and female patients with RHD were given 1.2 million IU of an undisclosed BPG formulation.²⁰⁷ Eighty six percent of patients had serum penicillin concentrations greater than 0.02 µg/ml on day 28 following injection. In Australia, 25 male and female patients received 1.2 million IU of BPG (*Bicillin L-A*, Wyeth) for RF prophylaxis.²⁰⁸ At day 14 only 11/16 (69%) had serum penicillin levels considered protective (0.025 µg/ml), by day 21 this fell to 8/16 (50%) and further to 4/17 (24%) by day 28.²⁰⁹ Pharmacokinetic modelling applied to BPG dosing suggests that the majority of children and adults given 1.2 million IU will have a serum penicillin level less than 0.02 µg/ml two weeks after injection.⁵⁹

A 2013 meta-analysis of 27 articles, including these and similar studies on BPG concentration, found that studies conducted after 1990 were associated with lower serum penicillin concentrations. This raises the possibility that changes in formulation or manufacturing before and after 1990 may be associated with variation in observed pharmacokinetics.²¹⁰ Variation in pharmacokinetic and bioavailability parameters between BPG formulations is supported by a 1996 study of 360 patients with RHD in Egypt.²¹¹ The change from older bioassays to contemporary quantitative assays may also have altered the sensitivity of measuring serum penicillin concentrations, although more sensitive modern methods would be expected to show longer rather than shorter duration of action.²¹¹

Overall the *in vivo* behaviour of BPG is poorly understood, despite the age and widespread use of the drug. Authors of these studies have suggested that the weight or age of participants, physical activity during the study period or BPG formulation may contribute to variability of results.²¹⁰ It is clear that more detailed studies of BPG pharmacokinetics are urgently needed, particularly to understand the behaviour of the drug when used in children and in the setting of increased body mass index. Use of a standardised assay would be helpful for interpreting the results of future studies.

Suitability for suspension

Clinicians report that difficulty suspending BPG powdered formulations for injection is considered a marker of a 'poor quality' product.¹⁸¹ There does seem to be some empiric evidence that BPG from different manufacturers is associated with different solubility and needle blocking.²¹² There are few records of regulatory agencies responding to these issues. However, in 2015 the Food and Drug Administration of the Philippines advised of a voluntary recall of two lots of the BPG product *Zalpen* (YSS Laboratories Co. Inc.) over concerns about inability to dilute the powder in fluid.²¹³

High rates of idiosyncratic adverse reactions

Highly anecdotal reports suggest that the rate of adverse reactions to BPG is higher than would be expected, given what is known about penicillin allergy. Reactions appear to be idiosyncratic, including possible syncope and systemic malaise after injection. These are often informally attributed to 'impurities' in BPG or other drug quality issues. It is impossible to interpret or investigate these cases without systemically collecting pharmacovigilance data to evaluate patterns of events. In the absence of clear evidence of idiosyncratic adverse reactions to BPG, clinicians should be educated about the expected prevalence of anaphylaxis and trained in its management.

ANTIBIOTIC RESISTANCE

Antibiotic resistance is one of the greatest threats to the delivery of modern health care.²¹⁴ Clinicians and policy makers are understandably concerned that increasing access to BPG – particularly the protracted courses of prophylaxis – may contribute to antibiotic resistance.²¹⁵

Target organisms treated with BPG remain exquisitely susceptible to penicillin. Although reassuring, the cause of persistent susceptible is poorly understood.

Treponema pallidum

There have been no documented cases of penicillin resistance in *T. pallidum*.²¹⁶ Serologic treatment failure does occur, often in the setting of HIV, or more commonly in association with reinfection. Relapse may also occur when *T. pallidum* enters the central nervous system and is therefore protected from treponemicidal levels of penicillin by the blood-brain barrier.²¹⁷ Theoretic pathways for development of *T. pallidum* resistance to penicillin do exist. However, over sixty years of susceptibility to penicillin suggests that the bacterial genetic mutations required for *T. pallidum* resistance are complex and evidently rare events.²¹⁶

Group A streptococci

There have been no documented cases of penicillin resistance in GAS.^{218,219} Persistent nasopharyngeal colonisation after BPG is relatively common but is attributable to a protected intracellular niche rather than true treatment failure.²²⁰ Continued susceptibility of GAS is particularly remarkable given high rates of nasopharyngeal carriage and widespread exposure to penicillin over many decades.²²¹ The mechanisms for this ongoing susceptibility remain unclear but may include prohibitively complex requirements for bacterial genetic transfer, toxicity associated with genes for resistance or evolutionary cost in the development of low-affinity penicillin binding proteins.²²²

There are also risks that widespread use of BPG could drive resistance in other, non-target, bacteria. Studies exploring this possibility have reported mixed results. In Israel, viridans streptococci cultured from children receiving monthly injections of BPG for prophylaxis of RF remained

sensitive to penicillin G and a number of other antibiotics.²²³ There was no significant change in resistance patterns relative to a control group of children not receiving BPG injections. Similarly, in Brazil, long term BPG therapy for RF prophylaxis did not alter penicillin susceptibility of oral flora *Str. sanguinis* and *Str. oralis*.²²⁴ However, widespread use of oral penicillins – particularly for viral infections – has been correlated with increased antibiotic resistance, particularly in *Str. pneumonia*.^{219,225}

The role of population dynamics in driving antibiotic resistance remains poorly understood. In overcrowded settings where children have multiple early infections and a high bacterial load, transfer resistance determining genetic material between organisms may be accelerated, irrespective of antibiotic use.²²⁶ However, in these settings the use of BPG in preference to newer, more expensive antibiotics may actually reduce the risk of population level antibiotic resistance. Alternatives to BPG for various indications include azithromycin and erythromycin, both of which are associated with widespread antibiotic resistance. Similarly, the intramuscular route of BPG ensures appropriate adherence for acute indications: it is impossible for patients to complete only partial courses, to share medications with others or to independently dose adjust. Relative to oral antibiotics, BPG is less amenable to the kind of misuse which drives resistance.

The use of antibiotics in developing countries requires special consideration but proven treatments should not be withheld from vulnerable populations. The Lancet Infectious Diseases Commission notes that RHD control programs equipped with a central register and a supply of BPG is an appropriate intervention and highlights that ‘the challenge in all these efforts will be to scale-up antibiotic used but to minimised drug resistance from unnecessary or inappropriate use’.²²⁷ Limiting use of BPG for appropriate indications, to be administered by trained health workers using agreed protocols (and diagnostic tests where available) provides the best opportunity to treat disease and minimise the development of resistance.

OPPORTUNITIES TO IMPROVE BPG

Options for product innovation or reformulation	34
Paediatric doses	34
Reduction of injection site pain	34
Longer acting formulations	34
Regulatory issues	35
The challenge of historic licensing data	35
Extending licensing to novel indications	36



OPTIONS FOR PRODUCT INNOVATION OR REFORMULATION

Paediatric doses

BPG is recommended for children, particularly for the treatment of syphilis (neonates) and for secondary prophylaxis against RF (commonly over 5 years of age). In some countries, BPG is widely used for treatment of impetigo in young children²²⁸ or primary prophylaxis of GAS pharyngitis. Some clinical guidelines recommend paediatric dosing by weight for these indications.^{26,228} However, neither powdered or liquid formulations of BPG are suitable for precise calculation of incremental doses. In practice, smaller doses are often calculated by volume of drug decanted into a smaller syringe. Practically, this entails suspending powdered products in diluent and then drawing up a fractional dose by volume, a process which assume the drug is evenly distributed in the diluent. This is associated with a high risk of under-dosing (potentially causing treatment failure) or over-dosing (increasing the risk of volume-related adverse events). Although the absolute number of children receiving BPG globally is modest, product innovation to facilitate paediatric dosing would be a valuable safety addition. For example, it may be possible to validate graduations or other markings on vials/syringes of existing formulations to indicate fractions of the medication dose.²²⁹ As a minimum intervention, increasing access to 0.6 million IU dose formulations should be supported.



Image credit: Daniel A. Anderson.
Preparation of an injection for syphilis treatment.

Reduction of injection site pain

Reducing the pain of BPG injections is a critical determinant of product acceptability. As discussed, pain following injection is moderate to severe and may last up to 48 hours after injection. This particularly reduces adherence to BPG prophylaxis when multiple doses are required. Further study is needed to better understand the determinants of BPG injection site pain.

In the interim, manufacturers and regulators should consider allowing or endorsing the use of lignocaine as a diluent for BPG injections. There is reasonable evidence that the practice is safe, it already recommended in a number of guidelines, and informal use of lignocaine is widespread. Providing definitive advice on how much lignocaine should be used and any restrictions on use would be a practical first step to mitigating injection site pain.

Other strategies to reduce pain may include developing formulations of BPG which are less likely to block the needle, producing high force/high velocity injections. There have been some preliminary attempts to develop BPG formulations more amenable to suspension.¹⁹³ Adjunct innovations, including improvements to syringes, diluent or suspension technique may be possible and should be explored.

Longer acting formulations

One of the major benefits of BPG is protracted serum penicillin concentrations. This feature makes BPG uniquely suitable for prophylaxis against sensitive organisms and underpins its existing role in prophylaxis. BPG may also be acceptable and convenient prophylaxis for other indications (hyposplenism prophylaxis, prevention of recurrent cellulitis) if the dose interval could be prolonged. Certainly, adherence to secondary prophylaxis in people living with RHD would be considerably enhanced by a longer acting, more acceptable formulation. Calls for reformulation of BPG have come from the RHD community but improved formulations may well be applicable to other indications.⁹ A small number of studies have explored opportunities for dose interval reformulation, including microemulsions,²³⁰ nanoparticles²³¹ and implantable drug monoliths. Efforts to develop a safe, quality assured, long-acting form of BPG are critical to global RHD control and are likely to enhance disease control efforts for other indications. Well designed trials to prove that sustained serum level above the MIC prevent GAS infection in prophylaxis are needed. Public-private research initiatives will then be required to identify candidate formulations and regulatory requirements.

REGULATORY ISSUES

Regulation of BPG is challenging, even for existing formulations. In the United Kingdom BPG remains entirely unlicensed, attributed by some authors as ‘probably due to low demand’.²³² Regulatory arrangements in other countries remain somewhat opaque, necessarily responsive to the formulations of BPG available for purchase.

The challenge of historic licensing data

Existing regulatory data on BPG are limited; in many cases licensing data predates the contemporary era of study design and evidence of efficacy. The US Centers for Disease Control and Prevention guidelines on the treatment of syphilis acknowledges ‘the effectiveness of penicillin for the treatment of syphilis was well established through clinical experience even before the value of randomised controlled clinical trials was recognised. Therefore, nearly all recommendations for the treatment of syphilis are based not only on clinical trials and observational studies, but many decades of clinical experience.’²⁶

The absence of historic data makes it difficult for manufacturers to demonstrate that their product can meet existing standards or demonstrate bioequivalence. Companies seeking to license any new BPG formulations may be mandated to complete studies which demonstrate the efficacy of penicillin against target organisms *per se*. This uncertainty about regulatory requirements is likely to have a chilling effect on new market entrants.

A number of older antimicrobials are candidates for ‘re-development’, a process which includes updating trial data to contemporary standards, conduct of high quality studies and clearly communicating to users appropriate indications for each product.²³³ BPG is an ideal candidate for the redevelopment process, particularly to define standard assays, pharmacokinetic profile, acceptable MIC and, for some indications, mechanism of action. Given the largely generic market for BPG, low volumes and limited profits of the product, manufacturers will be unable to support all of the work necessary to update regulatory dossiers for BPG. The requirements for redevelopment necessitates intellectual, financial and goodwill input from academia, regulators, industry, governments, international agencies, clinicians and communities.

Extending licensing to novel indications

There are a number of reformulation options for BPG, spanning from incremental improvement to substantial redevelopment of BPG into a less painful, longer acting formulation. Substantial reformulation may make the product acceptable for new indications, particularly prevention of cellulitis and in prophylaxis following hyposplenism. The United States FDA has issued guidance on the non-clinical safety evaluation of reformulated drug products and products intended for administration by an alternate route.²³⁴ In particular, they identify that it may be possible to ‘rely on the finding of safety and effectiveness of a listed drug and establish a clinical bridge to that listed drug’.²³⁴ Given the existing quality of regulatory data for BPG, the opportunity to bridge to existing listings is likely to be limited. Approval for a reformulated product or for novel indications is likely to be prohibitively complex unless regulatory dossiers for existing BPG can be updated.

ACTIONS AND RECOMMENDATIONS

Global actions	39
Regional actions	39
National actions	40
Local actions	40





High quality BPG is a safe, effective and affordable antibiotic for which there is decades of clinical experience. BPG remains the drug of choice for major indications because the target organisms – *Treponema pallidum* and group A streptococci - remain exquisitely sensitive. However, global shortages of BPG are common. These shortages increase the use of more expensive, less effective drugs which may accelerate development of resistance in other organisms. BPG remains an essential medicine and tangible steps are needed for it to be made safely available to the vulnerable populations who need it most.

The challenges of BPG – concerns about supply, safety, quality and end point use – are common to many older antibiotics, particularly sterile injectables. As the world confronts growing antibiotic resistance with few new antimicrobials there are increasingly urgent calls to optimize the use of older drugs. Specifically, ‘strategies are urgently needed to ‘re-develop’ these drugs to modern standards, integrating new knowledge into regulatory frameworks and communicating the knowledge from research bench to bedside’.²³³

GLOBAL ACTIONS

1. Convene stakeholders in the global BPG market to develop a joint strategy to revive and re-develop the drug.²³³ This Global Status of BPG Report, a formal market analysis and local consultation should provide background resources for decision making. Critical questions for this group should include:
 - A. What is the existing market and global demand for BPG?
 - B. How can existing manufactures and emerging manufactures be engaged to increase and sustain production in diverse geographies?¹¹³
 - C. What existing data are available to guide re-development of BPG? How can raw, unpublished and historic data best be shared?²³³

What are the unanswered scientific questions about BPG and which studies are required to answer these questions?²³³

 - D. What are the priority preferred product characteristics for reformulated products?²³⁵

What procurement mechanisms are most effective for BPG and can an appropriate lead agency be identified?

 - E. What are the best options for sustainable financing for BPG?
 - F. How should the price of BPG be set and should a price minimum be provided to encourage continuity of supply?¹⁴⁷
 - G. How will improvements in BPG supply and successful redevelopment of BPG be measured?
 - H. What is the best way to ensure effective communication between all stakeholders in the BPG supply chain?

REGIONAL ACTIONS

1. Develop regional partnerships with neighbouring countries that also require a supply of BPG, through seeking technical assistance and support from WHO regional offices.
2. Establish or integrate with existing regional procurement mechanisms, which:
 - A. Include emergency funds to guarantee payment for procurements of BPG in cases of stock outs;
 - B. Allow and encourage neighbouring countries to loan any excess stock of BPG medicines to each other in emergency situations;
 - C. Secure price reductions for BPG where appropriate.

NATIONAL ACTIONS

- 1. Review BPG recommendations in national Essential Medicines Lists and Formularies to ensure recommendations from the WHO Essential Medicines List have been incorporated.
- 2. Engage with ongoing efforts, led by the World Health Organization Secretariat, to develop a systematic approach to prevent and manage shortages of essential medicines, which include methods to support BPG manufacture and supply.¹⁴⁷
- 3. Include the procurement of BPG in national health budgets, as a cost-effective measure included in the WHO Package of Essential Noncommunicable Disease Interventions for Primary Health Care in Low Resource Settings (PEN) Package²³⁶ of interventions for non-communicable diseases.
- 4. Advocate for the WHO to replace the standard adult dose for BPG included in the current WHO Essential Medicines List for Children (EMLc)¹⁹ with a specific paediatric dose in the next edition of the EMLc in 2017.
- 5. Consider a national stakeholder mapping in order to identify all relevant in-country actors involved in the BPG supply chain. This may include manufacturers, suppliers, regulators, procurement agencies international partners, civil society organizations, government, patients, health care professionals, pharmacists, researchers and academics. Stakeholders representing different clinical indications for BPG (including syphilis and rheumatic heart disease) should be explicitly identified.
- 6. Establish a body or forum for discussion and decision-making about the BPG supply chain, ensuring that all relevant stakeholders are included.
- 7. Create an emergency national plan for cases of unpredictable shortages and stock outs where adequate or sufficient quality BPG is unavailable.
- 8. Define standardized protocols to fast-track alternative supplies of BPG in cases of shortages and stock outs,¹⁶⁰ including:
 - A. Qualifying criteria;
 - B. Mechanisms for flexibilities – creation of conditions of approval;
 - C. Agreed-upon standards to conform with stringent regulatory requirements;

- 9. Develop or support national pharmacovigilance programs to capture reports of adverse reactions to BPG and other drugs.²³⁷
- 10. Establish or strengthen country-led, integrated inventory and distribution management for BPG, including the monitoring of stock data.
- 11. Develop or support mechanisms for clinicians and communities to notify drug shortages or to be alerted of expected shortages.
- 12. Establish an effective communication mechanism among all stakeholders along the in-country supply chain.
- 13. Enhance country-led BPG data collection tools by collaborating with civil society.

LOCAL ACTIONS

- 1. Ensure clinical guidelines outline the appropriate indications for BPG.
- 2. Ensure all clinical staff giving BPG injections have received appropriate training in injection technique and management of complications including anaphylaxis.
- 3. Ensure that adrenaline is available when BPG injections are given.
- 4. Engage communities and people living with disease in redevelopment of BPG.

ANNEXES AND REFERENCES



ANNEXES

ANNEX A: Mapping of BPG National Essential Medicines Lists

<http://rhdaction.org/resources/mapping-bpg-national-essential-medicines-lists>

ANNEX B: Known trade names of BPG

<http://rhdaction.org/resources/known-trade-names-benzathine-penicillin-g>

REFERENCES

- World Health Organisation. Essential medicines and health products: International Nonproprietary Names. 2016. <http://www.who.int/medicines/services/inn/en/> (accessed 3 May 2016 2016).
- Medsafe. Benzathine Benzylpenicillin Injection for deep IM injection only. 2012. <http://www.medsafe.govt.nz/profs/Datasheet/b/BicillinLAinj.pdf> (accessed 2 May 2016 2016).
- Yocum RR, Rasmussen JR, Strominger JL. The mechanism of action of penicillin. Penicillin acylates the active site of *Bacillus stearothermophilus* D-alanine carboxypeptidase. *Journal of Biological Chemistry* 1980; **255**(9): 3977-86.
- Yocum RR, Amanuma H, O'Brien TA, Waxman DJ, Strominger JL. Penicillin is an active-site inhibitor for four genera of bacteria. *Journal of Bacteriology* 1982; **149**(3): 1150-3.
- Wright AJ. The penicillins. *Mayo Clinic Proceedings* 1999; **74**(3): 290-307.
- Chain E, Florey HW, Adelaide MB, et al. PENICILLIN AS A CHEMOTHERAPEUTIC AGENT. *The Lancet* 1940; **236**(6104): 226-8.
- Szabo JL, Edwards CD, Bruce WF. N,N'-dibenzylethylenediamine penicillin: preparation and properties. *Antibiotics & chemotherapy* 1951; **1**(8): 499-503.
- Stollerman GH, Rusoff JH. Prophylaxis against group A streptococcal infections in rheumatic fever patients; use of new repository penicillin preparation. *J Am Med Assoc* 1952; **150**: 1571-5.
- Wyber R, Taubert K, Marko S, Kaplan EL. Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvement. *Global Heart* 2013; **8**(3): 227-34.
- Currie B. Benzathine penicillin - Down but not out. *Northern Territory Dis Control Bull* 2006; **13**: 1-13.
- Miller EL. The penicillins: A review and update. *Journal of Midwifery & Women's Health* 2002; **47**(6): 426-34.
- Broderick MP, Hansen CJ, Russell KL, Kaplan EL, Blumer JL, Faix DJ. Serum Penicillin G Levels Are Lower Than Expected in Adults within Two Weeks of Administration of 1.2 Million Units. *PLoS one* 2011; **6**(10): e25308.
- Recommendations of the International Conference on Penicillin. *Science* 1945; **101**(2611): 42-3.
- Pfizer. BICILLIN L-A- penicillin g benzathine injection, suspension 2015. <http://labeling.pfizer.com/ShowLabeling.aspx?id=691> (accessed 3 May 2016).
- MSH. Drug Price Search - International Drug Price Indicator Guide. 2014. http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=BBP12A&s_year=2014&year=2014&str=1%2E2M%20IU&desc=Penicillin%2C%20Benzathine%20Benzyl&pack=new&frm=POWDER&rte=INJ&class_code2=06.2.1.&supplement=&class_name=Beta%20lactam%20medicines (accessed February 20 2016).
- World Health Organization. Essential medicines and health products. 2016. http://www.who.int/medicines/services/essmedicines_def/en/ (accessed 3 May 2016 2016).
- World Health Organization. National Medicines List/Formulary/Standard Treatment Guidelines. 2016. http://www.who.int/selection_medicines/country_lists/en/ (accessed 3 May 2016 2016).
- World Health Organization. Comparative Table of Medicines on the WHO Essential Medicines List from 1977-2011. 2011. http://www.who.int/selection_medicines/list/en/ (accessed 3 May 2016 2016).
- World Health Organization. 5th WHO Model List of Essential Medicines for Children (April 2015). 2015 http://www.who.int/medicines/publications/essentialmedicines/EMLc_2015_FINAL_amended_AUG2015.pdf?ua=1 (accessed 3 May 2016).
- PATH, World Health Organization, United Nations Population Fund. Essential Medicines for Reproductive Health: Guiding Principles for Their Inclusion on National Medicines Lists. Seattle: PATH, 2006.
- World Health Organization. The interagency emergency health kit 2011: medicines and medical devices for 10 000 people for approximately three months. Geneva: World Health Organization, 2011.
- Newman L, Rowley J, Hoorn SV, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. *PLoS one* 2015; **10**(12).
- World Health Organization. Guidelines for the Management of Sexually Transmitted Infections. http://www.who.int/reproductivehealth/topics/rtis/treatment_syphilis.pdf (accessed 3 May 2016 2016).
- Douglas JM. Penicillin treatment of syphilis. *JAMA* 2009; **301**(7): 769-71.
- Janier M, Hegyi V, Dupin N, et al. 2014 European guideline on the management of syphilis. *Journal of the European Academy of Dermatology and Venereology* 2014; **28**(12): 1581-93.
- Centers for Disease Control. 2015 Sexually Transmitted Diseases Treatment Guidelines. 2015. <http://www.cdc.gov/std/tg2015/syphilis.htm> (accessed 3 May 2016 2016).
- Chen XS, Yin YP, Wei WH, et al. High prevalence of azithromycin resistance to *Treponema pallidum* in geographically different areas in China. *Clinical Microbiology and Infection* 2013; **19**(10): 975-9.
- World Health Organization. The Global elimination of congenital syphilis : rationale and strategy for action., 2007.
- World Health Organization. Investment case for eliminating mother-to-child transmission of syphilis: Promoting better maternal and child health and stronger health systems. Geneva: World Health Organization, 2012.
- Klausner JD. The sound of silence: missing the opportunity to save lives at birth. *Bulletin of the World Health Organization* 2013; **91**(3): 158-A.
- Schmid G. Economic and programmatic aspects of congenital syphilis prevention. *Bulletin of the World Health Organization* 2004; **82**(6): 402-9.
- World Health Organization. Draft global health sector strategy on sexually transmitted infections 2016 - 2021: World Health Organization, 2015.
- Marks M, Solomon AW, Mabey DC. Endemic treponemal diseases. *Transactions of the Royal Society of Tropical Medicine and Hygiene* 2014; **108**(10): 601-7.
- World Health Organization. Yaws and other endemic treponematoses. 2016. <http://www.who.int/yaws/en/> (accessed 3 May 2016).
- Mitjà O, Šmajš D, Bassat Q. Advances in the Diagnosis of Endemic Treponematoses: Yaws, Bejel, and Pinta. *PLoS neglected tropical diseases* 2013; **7**(10): e2283.
- Mitjà O, Mabey D. Yaws, bejel, and pinta. 2015. http://www.uptodate.com/contents/yaws-bejel-and-pinta?source=outline_link&view=text (accessed 28 April 2016 2016).
- Elimination of yaws in India. *Relevé épidémiologique hebdomadaire / Section d'hygiène du Secrétariat de la Société des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations* 2008; **83**(15): 125-32.
- World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases – A roadmap for implementation. World Health Organization, 2012.
- Mitjà O, Hays R, Ipai A, et al. Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: An open-label, non-inferiority, randomised trial. *The Lancet* 2012; **379**(9813): 342-7.
- Eradication of yaws—the Morges strategy. *Relevé épidémiologique hebdomadaire / Section d'hygiène du Secrétariat de la Société des Nations = Weekly epidemiological record / Health Section of the Secretariat of the League of Nations* 2012; **87**(20): 189-94.
- Mitjà O, Houine W, Moses P, et al. Mass treatment with single-dose azithromycin for yaws. *New England Journal of Medicine* 2015; **372**(8): 703-10.
- Carapetis JR, Steer AC, Mulholland EK. The current evidence for the burden of group A streptococcal diseases (WHO/FCH/CAH/05.07). Geneva: World Health Organization; 2004.
- Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group a streptococcal pharyngitis: 2012 update by the infectious diseases society of America. *Clinical Infectious Diseases* 2012; **55**(10): e86-e102.
- Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. *Lancet* 2005; **366**(9480): 155-68.
- Carapetis J, Steer A, Mulholland E, Weber M. The global burden of group A streptococcal diseases. *Lancet Infectious Diseases* 2005; **5**(11): 685-94.
- Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: A meta-analysis. *BMC Cardiovascular Disorders* 2005; **5**.
- Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. *CochraneDatabaseSystRev* 2000: CD000023.

REFERENCES

48. Zühlke LJ, Karthikeyan G. Primary Prevention for Rheumatic Fever. *Global Heart*; **8**(3): 221-6.
49. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. *Circulation* 2009; **119**(11): 1541-51.
50. RHD Australia (ARF/RHD writing group). The Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (2nd edition), 2012.
51. Wilson N. Secondary prophylaxis for rheumatic fever: Simple concepts, difficult delivery. *World Journal for Pediatric and Congenital Heart Surgery* 2013; **4**(4): 380-4.
52. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; **380**(9859): 2197-223.
53. Collaborators GMAoD. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*; **385**(9963): 117-71.
54. Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. *The Lancet*; **386**(9995): 743-800.
55. Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. *Nature Reviews Disease Primers* 2016; **2**: 15084.
56. Watkins DA, Mvundura M, Nordet P, Mayosi BM. A cost-effectiveness analysis of a program to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba. *PloS one* 2015; **10**(3).
57. Wyber R, Carapetis J. Evolution, evidence and effect of secondary prophylaxis against rheumatic fever. *Journal of the Practice of Cardiovascular Sciences* 2015; **1**(1): 9 - 14.
58. Manyemba J, Mayosi BM. Intramuscular penicillin is more effective than oral penicillin in secondary prevention of rheumatic fever--a systematic review. *S Afr Med J* 2003; **93**: 212-8.
59. Neely M, Kaplan EL, Blumer JL, Faix DJ, Broderick MP. A population pharmacokinetic modeling approach shows that serum penicillin G concentrations are below inhibitory concentrations by two weeks after benzathine penicillin G injection in the majority of young adults. *Antimicrobial Agents and Chemotherapy* 2014; **58**(11): 6735-41.
60. Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. *Cochrane Database Syst Rev* 2002: CD002227.
61. Spinetto H, Lennon D, Horsburgh M. Rheumatic fever recurrence prevention: A nurse-led programme of 28-day penicillin in an area of high endemicity. *Journal of Paediatrics and Child Health* 2011; **47**(4): 228-34.
62. WHO. Rheumatic fever and rheumatic heart disease. Geneva: World Health Organization, 2001.
63. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: A scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care. *Circulation* 2009; **119**(11): 1541-51.
64. Saxena A, Krishna K, Gera RPK, Radhakrishnan S, Mishra S, Ahmed Z. Consensus guidelines on Pediatric Acute Rheumatic Fever and Rheumatic Heart Disease. *Indian Pediatrics* 2008; **45**: 565-73.
65. National guidelines on primary prevention and prophylaxis of rheumatic fever (RF) and rheumatic heart disease (RHD) for health professionals at primary level: Western Cape Government, South Africa, 2003.
66. Zühlke L, Mirabel M, Marijon E. Congenital heart disease and rheumatic heart disease in Africa: Recent advances and current priorities. *Heart* 2013; **99**(21): 1554-61.
67. World Heart Federation, RhEACH, Medtronic Foundation. RHD Action. 2016. <http://rhdaction.org/> (accessed 3 May 2016 2016).
68. Wyber R, Grainger Gasser A, Thompson D, et al. Tools for Implementing RHD Control Programmes (TIPS) Handbook. Perth, Australia: World Heart Federation RhEACH, 2014.
69. van Dam J, Tadmor B, Spector J, et al. An open-access mobile compatible electronic patient register for rheumatic heart disease ('eRegister') based on the World Heart Federation's framework for patient registers. *Cardiovascular Journal of Africa* 2015; **26**(6): 227-33.
70. Rothenbuhler M, O'Sullivan CJ, Stortecky S, et al. Active surveillance for rheumatic heart disease in endemic regions: a systematic review and meta-analysis of prevalence among children and adolescents. *The Lancet Global health* 2014; **2**(12): e717-26.
71. Addis Ababa Communiqué on Eradication of Rheumatic Heart Disease in Africa, 2015.
72. Watkins D, Zuhlke L, Engel M, et al. Seven key actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communique. *Cardiovasc J Afr* 2016; **27**: 1-5.
73. Remenyi B, Carapetis J, Wyber R, Taubert K, Mayosi BM. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. *Nature Reviews Cardiology* 2013; **10**(5): 284-92.
74. McDonald M, Currie BJ, Carapetis JR. Acute rheumatic fever: a chink in the chain that links the heart to the throat? *Lancet Infect Dis* 2004; **4**: 240-5.
75. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. *The Lancet Infectious Diseases* 2005; **5**(11): 685-94.
76. Bowen AC, Mahe A, Hay RJ, et al. The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma. *PloS one* 2015; **10**(8): e0136789.
77. Clucas DB, Carville KS, Connors C, Currie BJ, Carapetis JR, Andrews RM. Disease burden and health-care clinic attendances for young children in remote Aboriginal communities of northern Australia. *Bulletin of the World Health Organization* 2008; **86**(4): 275-81.
78. Koning S, Verhagen A, Suijlekom-Smit L, Morris A, Butler C, Wouden J. Interventions for impetigo (mm ref 2139). *Cochrane Database Syst Rev* 2004; **2**: CD003261.
79. Bowen AC, Tong SYC, Andrews RM, et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: An open-label, randomised, controlled, non-inferiority trial. *The Lancet* 2014; **384**(9960): 2132-40.
80. Waghorn DJ. Overwhelming infection in asplenic patients: Current best practice preventive measures are not being followed. *Journal of Clinical Pathology* 2001; **54**(3): 214-8.
81. Makris M, Greaves M, Winfield DA, Preston FE, Lilleyman JS. Long term management after splenectomy: Lifelong penicillin unproved in trials...[3]. *British Medical Journal* 1994; **308**(6921): 131-2.
82. Spelman D, Buttery J, Daley A, et al. Guidelines for the prevention of sepsis in asplenic and hyposplenic patients. *Internal Medicine Journal* 2008; **38**(5): 349-56.
83. de Montalembert M, Lenoir G. Antibiotic prevention of pneumococcal infections in asplenic hosts: Admission of insufficiency. *Annals of Hematology* 2004; **83**(1): 18-21.
84. Pav V, Nahata M. Duration of penicillin prophylaxis in sickle cell anaemia: issues and controversies. *Pharmacotherapy* 2000; **20**(1): 110 - 7.
85. Gaston M, Verter J, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anaemia. A randomized trial. . *New England Journal of Medicine* 1986; **314**(25): 1593 - 9.
86. Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease (Review). *Cochrane Database of Systematic Reviews* 2014; (11): Art. No.: CD003427.
87. Davies JM, Barnes R, Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. *Clinical Medicine* 2002; **2**(5): 440-3.
88. U.S Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report 2014, 2014.
89. Alli NA, Patel M, Alli HD, et al. Recommendations for the management of sickle cell disease in South Africa. *South African Medical Journal* 2014; **104**(11): 743-51.
90. Buchanan GR, Smith SJ. Pneumococcal Septicemia Despite Pneumococcal Vaccine and Prescription of Penicillin Prophylaxis in Children With Sickle Cell Anemia. *American Journal of Diseases of Children* 1986; **140**(5): 428-32.
91. Anglin DL, Siegel JD, Pacini DL, Smith SJ, Adams G, Buchanan GR. Effect of penicillin prophylaxis on nasopharyngeal colonization with Streptococcus pneumoniae in children with sickle cell anemia. *The Journal of Pediatrics* 1984; **104**(1): 18-22.
92. Cummins D, Heuschkel R, Davies SC. Penicillin prophylaxis in children with sickle cell disease in Brent. *British Medical Journal* 1991; **302**(6783): 989-90.
93. Cober M, Phelps S. Penicillin prophylaxis in children with sickle cell disease. *The Journal of Pediatric Pharmacology and Therapeutics* 2010; **15**(3): 152 - 25.
94. Knight-Madden J, Serjeant GR. Invasive pneumococcal disease in homozygous sickle cell disease: Jamaican experience 1973-1997. *The Journal of Pediatrics* 2001; **138**(1): 65-70.

REFERENCES

95. McNamara DR, Tleyjeh IM, Barbari EF, et al. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. *Archives of Internal Medicine* 2007; **167**(7): 709-15.
96. Oh CC, Ko HCH, Lee HY, Safdar N, Maki DG, Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: A systematic review and meta-analysis. *Journal of Infection* 2014; **69**(1): 26-34.
97. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. *Journal of Investigative Dermatology* 2014; **134**(6): 1527-34.
98. Chakroun M, Ben Romdhane F, Battikh R, Souki A, Bouzouaia N. Benzathine penicillin prophylaxis in recurrent erysipelas. *Medecine et Maladies Infectieuses* 1994; **24**(10): 894-7.
99. Mason JM, Thomas KS, Crook AM, et al. Prophylactic antibiotics to prevent cellulitis of the leg: Economic analysis of the patch I & II trials. *PloS one* 2014; **9**(2).
100. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2014; **59**(2): 147-59.
101. Johnson L, Stricker R. The Infectious Diseases Society of America Lyme guidelines: a cautionary tale about the development of clinical practice guidelines. *Philosophy, Ethics and Humanities in Medicine* 2010; **5**(9): doi: 10.1186/747-5341-5-9.
102. Taubert K, Marko SB. Access to Essential Medicines: Illuminating Disparities in the Global Supply of Benzathine Penicillin G in the Context of Rheumatic Fever / Rheumatic Heart Disease Prevention. *Journal of the American College of Cardiology* 2013; **61**(10_S).
103. Marko S. Benzathine Penicillin G for the Prevention of Rheumatic Fever and Rheumatic Heart Disease in the Developing World: A Global Survey of the Quality and Quantity of Supply [Masters Theses]: University of Connecticut 2014.
104. WHO. Technical consultation on preventing and managing global stock outs of medicines. 2015; Geneva, Switzerland: World Health Organization; 2015.
105. Online C. Nepalese Heart Patients at Risk due to Drug Shortage. 28 May 2003 2003. <http://english.cri.cn/144/2003-5-28/19@15811.htm> (accessed 8 May 2016 2016).
106. Lucas S. L'implication du pharmacien inspecteur de sante publique dans le dispositif de prévention et de gestion des ruptures de stock et d'approvisionnement de médicaments : analyse et perspectives: École des hautes études en santé publique; 2014.
107. Neelakantan V. The campaign against yaws in postcolonial Indonesia. *The Newsletter*, 2014. http://iiias.asia/sites/default/files/IIAS_NL69_1011.pdf (accessed 8 May 2016).
108. Poland relies on direct imports to cope with shortage of benzathine benzylpenicillin. 2014. <http://ceepharm.com/news/218851/poland-relies-on-direct-imports-to-cope-with-shortage-of-benzathine-benzylpenicillin> (accessed 5 May 2016 2016).
109. Ministry of Health Central Administration for Pharmaceutical Affairs Drug Shortage. 2015. http://www.eda.mohealth.gov.eg/Files/786_DS_September_2015.pdf (accessed 8 May 2016 2016).
110. Pfizer. Bicillin LA 2.3mL (Benzathine benzylpenicillin injection) Product Information. Sydney: Pfizer; 2012.
111. Australian Government. Pharmaceutical Benefits Scheme: Benzathine Benzylpenicillin. 2016. <http://www.pbs.gov.au/medicine/item/2267H-5027N> (accessed 9 May 2016 2016).
112. Stoneman J, Taylor SJ. Improving access to medicines in urban, regional and rural Aboriginal communities--is expansion of Section 100 the answer? *Rural and remote health* 2007; **7**(2): 738.
113. Wyber R, Johnson TD, Patel B. Supply of benzathine penicillin G: the 20-year experience in Australia. *Australian and New Zealand Journal of Public Health* 2015; **39**(6): 506-8.
114. Currie BJ. Benzathine penicillin - down but not out (*mm ref 2846*). *NT Dis Control Bull* 2006; **13**: 1-5.
115. Kerndt P. Clinical Practice Alert: Ensuring an Adequate Supply of Benzathine Penicillin G. Los Angeles (CA): County of Los Angeles Public Health Sexually Transmitted Disease Program; 2006.
116. Lan G. Availability of Benzathine Penicillin (reply). *inTouch* 2006; **23**(8):6).
117. Crowhurst A, Duke C. Reinstatement of Bicillin LA Darwin, Australia: Best practice communique. In: Service DoHaC, editor.: Northern Territory Government; 2008.
118. Grohlman D. INTERRUPTION TO SUPPLY: Bicillin LA® IV (benzathine benzylpenicillin) 900 mg/2mL Pre-Filled Syringe. 2014. <https://www.rhdaustralia.org.au/news/interruption-supply-bicillin-la>.
119. Ministério da Saúde. Relação Nacional de Medicamentos Essenciais RENAME. Brasília - DF: Ministério da Saúde, Brasília, 2010, 7th edition.
120. Conselho Regional de Enfermagem. Declarar sem efeito a nomeação de Luis Carlos Fernandes da Silva, realizada por meio da Portaria nº 128/2013, e, Nomear candidatos subsequentes para o cargo de provimento efetivo de Agente Administrativo do Coren-RN. 2014. <http://www.coren.rn.gov.br/portarias.php> (accessed 2016 January 10).
121. Conselho Federal de Enfermagem. DECISION COFEN No. 0094/2015. 2015 (accessed January 10 2016).
122. Lenharo M. Falta de penicilina benzatina, que trata sífilis, preocupa médicos no Brasil. 2015. <http://g1.globo.com/bemestar/noticia/2015/06/falta-de-penicilina-benzatina-que-trata-sifilis-preocupa-medicos-no-brasil.html> (accessed December 17 2015).
123. Começa debate sobre falta de penicilina na rede do SUS. 2015. <http://www2.camara.leg.br/camaranoticias/noticias/SAUDE/497081-COMECA-DEBATE-SOBRE-FALTA-DE-PENICILINA-NA-REDE-DO-SUS.html> (accessed January 9 2016).
124. Management. CfP. Access to Essential Medicines: State of Minas Gerais, Brazil 2001. Arlington, VA. : Managment Sciences for Health, 2003.
125. Macinko J, Harris J. Brazil's Family Health Strategy — Delivering Community-Based Primary Care in a Universal Health System. *New England Journal of Medicine* 2015; **372**: 2177-81.
126. China Food and Drug Administration. China Food and Drug Administration. 2016. <http://eng.sfda.gov.cn/WS03/CL0755/> (accessed 12 May 2016 2016).
127. Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. *Journal of Global Health* 2013; **3**(1).
128. Fang H. The Chinese Health Care System, 2015: The Commonwealth Fund, 2015.
129. DXY. DXY Homepage. 2016. <http://www.dxy.cn/> (accessed 10 Mat 2016 2016).
130. DXY. 2016. <http://yao.dxy.cn/> (accessed 10 May 2016 2016).
131. Lun Z. Benzathine penicillin out of sorts? 2016. http://www.yyjib.com/html/2016-02/15/content_234913.htm (accessed 9 May 2016 2016).
132. Edge L. Emergency and more long-acting penicillin. *Healthy Times*. 2016 February 1 2016.
133. India Go. National List of Essential Medicines of India, 2011.
134. Government of India. National List of Essential Medicines: Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2003.
135. Indian Pharmacopoeia Commission. National Formulary of India: Government of India, Ministry of Health and Family Welfare, Indian Pharmacopoeia Commission, 2011.
136. Kumar R, Sharma M. Jai Vigyan Mission Mode Project. Community control of rheumatic fever / rheumatic heart disease in India. Comprehensive project report 2000 - 2010. Ansai Ngar, New Delhi: Indian Council of Medical Research, 2010.
137. Government of India. Government of India, Ministry of Chemicals and Fertilizers, National Pharmaceutical Pricing Authority. 2007. <http://www.nppaindia.nic.in/ceiling/press14feb07/14-2-07-hal.html> (accessed October 23 2015).
138. National Department of Health South Africa. Standard Treatment Guidelines and Essential Medicines List for South Africa: Hospital Level, Adults. 2012. http://www.kznhealth.gov.za/pharmacy/edladult_2012.pdf (accessed 5 May 2016).
139. National Department of Health South Africa. South African Medicine Price Registry. 2016. <http://www.mpr.gov.za/> (accessed 9 May 2016).
140. Government of South Africa. MEC Sibongiseni Dhlomo: Statement on shortage of essential medicines. In: Health K-N, editor.: Government of South Africa; 2015.
141. SA Running out of Penicillin. 2015. <http://www.health24.com/Lifestyle/Live-allergy-free/SA-running-out-of-penicillin-20150526> (accessed 8 May 2016 2016).
142. Consortium SAMEM. Stop Stock Outs. 2016. <http://stockouts.org/index.html> (accessed 9 May 2016 2016).
143. República Democrática de Timor-Leste Ministério da Saúde. Essential Medicines List for Timor Leste (EMTL) 2010. 2010.
144. Scolnik D, Aronson L, Lovinsky R, et al. Efficacy of a Targeted, Oral Penicillin—Based Yaws Control Program among Children Living in Rural South America. *Clinical Infectious Diseases* 2003; **36**(10): 1232-8.
145. U.S Food and Drug Administration. FDA Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to FDA. 2016. http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Penicillin%20G%20Benzathine%20%28Bicillin%20L-A%29%20Injection&st=c&tab=tabs-1 (accessed 5 May 2016 2016).

REFERENCES

146. Public Health Agency of Canada. Interim Syphilis Treatment Guidelines during the Benzathine Penicillin G (Bicillin L-A) Shortage 2016. 2016.
147. World Health Organization Secretariat. Addressing the global shortages of medicines, and the safety and accessibility of children's medication. Sixty-Ninth World Health Assembly; 2016 24 March 2016; Geneva, Switzerland; 2016.
148. Gehrett BK. A prescription for drug shortages. *JAMA* 2012; **307**(2): 153-4.
149. Kaplan W, Laing R. Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines. An Overview of Key Concepts, Issues and Opportunities for Future Research. Washington, DC: The International Bank for Reconstruction and Development / The World Bank 2005.
150. The National Academies Press. Box 4-1: The Medicines Manufacturing Process. In: Gostin GO, Buckley GJ, editors. Countering the Problem of Falsified and Substandard Drugs 2013.
151. World Health Organization. WHO statement following issue of EU Statement of Non-compliance with EUGMP to North China Pharmaceutical Group Semisynth Co., Ltd active pharmaceutical ingredient manufacturing facility in Shijiazhuang, Hebei, P.R. China. In: Prequalifications of Medicines Programme, editor.: World Health Organization;; 2015.
152. Supply Chain Management System. Recall Announcements: February 2015 Product Recall: Benzylpenicillin Procaine and Benzylpenicillin Benzathine. 2015. http://scms.pfscm.org/scms/ecatalog/recall_archive (accessed 10 May 2016 2016).
153. French National Agency for Medicines and Health Products Safety. Statement of Non-Compliance with GMP, Report No: 14MPP092. EudraGMDP, 2014.
154. Republic of the Philippines Supreme Court Manila. THE DEPARTMENT OF HEALTH, SECRETARY MANUEL M. DAYRIT, USEC. MA. MARGARITA GALON and USEC. ANTONIO M. LOPEZ, Petitioners, vs. PHIL. PHARMAWEALTH, INC., Respondent. In: Manila RotPSC, editor. GR No 169304. Philippine Laws and Jurisprudence Databank: The LAWPHil Project, Arellano Law Foundation; 2007.
155. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination, 2013.
156. Simms I, Wallace L, Thomas D, et al. Recent outbreaks of infectious syphilis, United Kingdom, January 2012 to April 2014. *Euro Surveill* 2014; **19**: 24.
157. Northern Territory Government. Syphilis outbreak update. In: Health Do, editor. Surveillance Update: Centre for Disease Control; 2016.
158. Government of India, Ministry of Chemicals and Fertilizers, National Pharmaceutical Pricing Authority. Price Notifications: F. NO. 8 (7)/2007/DP/NPPA-Div.II. 2007.
159. MSH. International Drug Price Indicator Guide 2014 Edition. Medford, Mass: Managment Sciences for Health, 2015.
160. World Health Organization. Technical Consultation on Preventing and Managing Global Stock Outs of Medicines. Geneva: World Health Organization, 2015.
161. United Nations Relief and Works Agency for Palestine Refugees in the Near East. Expression of Interest no: EO/2015/CPS/0001 to Manufacturers of Pharmaceuticals. 2015.
162. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *The Lancet* 2000; **356**(9237): 1255-9.
163. Cobert B, Biron P. Practical drug safety from A to Z: Jones & Bartlett Publishers; 2009.
164. Trubiano JA, Cairns KA, Evans JA, et al. The prevalence and impact of antimicrobial allergies and adverse drug reactions at an Australian tertiary centre. *BMC infectious diseases* 2015; **15**(1): 1-5.
165. Idsoe O, Guthe T, Willcox RR, de Weck AL. Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. *Bulletin of the World Health Organization* 1968; **38**(2): 159-88.
166. Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. *Allergy: European Journal of Allergy and Clinical Immunology* 2009; **64**(2): 183-93.
167. Blanca Gomez M, Torres MJ, Mayorga C, et al. Immediate allergic reactions to betalactams: Facts and controversies. *Current Opinion in Allergy and Clinical Immunology* 2004; **4**(4): 261-6.
168. Albin S, Agarwal S. Prevalence and characteristics of reported penicillin allergy in an urban outpatient adult population. *Allergy and Asthma Proceedings* 2014; **35**(6): 489-94.
169. Patterson R, Grammer LC, Greenberger PA. Patterson's allergic diseases: Lippincott Williams & Wilkins; 2009.
170. Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. *Drug Safety* 2007; **30**(8): 705-13.
171. Apter AJ, Kinman JL, Bilker WB, et al. Represcription of penicillin after allergic-like events. *Journal of Allergy and Clinical Immunology* 2004; **113**(4): 764-70.
172. Galvao TF, Silva MT, Serruya SJ, et al. Safety of Benzathine Penicillin for Preventing Congenital Syphilis: A Systematic Review. *PloS one* 2013; **8**(2).
173. International Rheumatic Fever Study Group. Allergic reaction long term benzathine penicillin prophylaxis for rheumatic fever *Lancet* 1991; **337**(8753): 1308-10.
174. International Rheumatic Fever Study G. Allergic reactions to long-term benzathine penicillin prophylaxis for rheumatic fever. *The Lancet* 1991; **337**(8753): 1308-10.
175. Regmi P, Upadhyaya A. Allergic reaction to long – term Benzathine penicillin injection for secondary prevention of acute rheumatic fever and recommendations for skin testing. 2013 2013; **8**(1): 3.
176. Kaya A, Erkoço lu M, enkon OG, et al. Confirmed penicillin allergy among patients receiving benzathine penicillin prophylaxis for acute rheumatic fever. *Allergologia et Immunopathologia* 2014; **42**(4): 289-92.
177. Cooper C. Safety of Long Term Therapy with Penicillin and Penicillin Derivatives. In: Administration USFaD, editor.: U.S Department of Health and Human Services; 2001.
178. Hsu I, Evans JM. Untoward reactions to benzathine penicillin G in a study of rheumatic-fever prophylaxis in adults. *New England Journal of Medicine* 1958; **259**(12): 581-3.
179. Steigmann F, Suker JR. Fatal Reactions to Benzathine Penicillin G: Report of Three Cases and Discussion of Contributory Factors. *JAMA: The Journal of the American Medical Association* 1962; **179**(4): 288-90.
180. World Health Organization. Benzathine penicillin - three fatal reports following mega-unit injections. *WHO Pharmaceuticals Newsletter* 2000; **4**: 22.
181. Regmi PR, Wyber R. Prevention of Rheumatic Fever and Heart Disease: Nepalese Experience. *Global Heart* 2013; **8**(3): 247-52.
182. Kumar K. Epidemiology of Rheumatic Fever and Rheumatic Heart Disease in India. In: Kumar K, ed. Ecab Clinical Update: Cardiology. India; 2008.
183. Kumar R, Sharma M. Jai Vigyan Mission Mode Project. Community Control of Rheumatic Fever / Rheumatic Heart Disease in India, Comprehensive Project Report (2000-2010). New Dehli: Indian Council of Medical Research, 2010.
184. Musuku J. Improving Access to Secondary Prevention of RHD: Mitigating Fear of Anaphylactic Penicillin Allergy in Zambia. PASCAR Annual Meeting. Mauritius; 2015.
185. IFPMA: Developing World Health Partnerships Directory. Rheumatic Heart Disease Program in Zambia. 2016. <http://partnerships.ifpma.org/partnership/rheumatic-heart-disease-program-in-zambia> (accessed 9 May 2016 2016).
186. Musuku J, Long A, Somwe SW, Habanyama G, Tadmor B, Spector JM. PW354 Improving Access To Secondary Prevention of Rheumatic Heart Disease: Mitigating Fear of Anaphylactic Penicillin Allergy In Zambia. *Global Heart* 2014; **9**(1): e331.
187. Russell K, Nicholson R, Naidu R. Reducing the pain of intramuscular benzathine penicillin injections in the rheumatic fever population of Counties Manukau District Health Board. *Journal of Paediatrics and Child Health* 2013; **50**(2): 112-7.
188. Morsy M, Mohamed M, Abosedira M, et al. Lidocaine as a diluent for benzathine penicillin G reduces injection pain in patients with rheumatic fever: a prospective, randomized, double-blinded crossover study. *Australian Journal of Basic and Applied Sciences* 2012; **6**(5): 236-40.
189. Bowen A, Tong S, Andrews R. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled non-inferiority trial. *The Lancet* 2014; **384**(9960): 2132-40.
190. Francis JR, Wyber R, Remenyi B, Croser D, Carapetis J. Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease. *IDCases* 2016; **4**: 6-7.
191. Hopkins U, Arias C. Large-volume IM injections: A review of best practices. *Oncology Nurse Advisor* 2013; **January / February**.
192. Nicoll LH, Hesby A. Intramuscular injection: an integrative research review and guideline for evidence-based practice. *Applied Nursing Research* 2002; **15**(3): 149-62.
193. Weli AM, Saddar E, Hiremath JG, Balamurugan M. Preparation and characterization of Benzathine Penicillin G solid dispersions using different hydrophilic carriers. *International Journal of Drug Delivery* 2013; **5**(4): 420-9.
194. RHD Australia. Administering Bicillin: reducing pain, stress and inconvenience experienced by patients who need 3 – 4 weekly IM Bicillin LA. 2016. <https://www.rhdaustralia.org.au/resources/administering-bicillin-reducing-pain-stress-and-inconvenience-experienced-patients-who> (accessed 10 May 2016 2016).

REFERENCES

195. Sartorius G, Fennell C, Spasevska S, Turner L, Conway AJ, Handelsman DJ. Factors influencing time course of pain after depot oil intramuscular injection of testosterone undecanoate. *Asian Journal of Andrology* 2010; **12**(2): 227-33.
196. Harrington Z, Thomas D, Currie B, Bulkanhawuy J. Challenging perceptions of non-compliance with rheumatic fever prophylaxis in a remote Aboriginal community. *Medical Journal of Australia* 2006; **184**: 514-7.
197. Tullu MS, Gandhi A, Ghildiyal RG. Benzathine penicillin prophylaxis in children with rheumatic fever (RF)/rheumatic heart disease (RHD): a study of compliance. *Al Ameen J Med Sci* 2010; **3**(2): 140-5.
198. Musoke C, Mondo C, Okello E, et al. Benzathine penicillin adherence for secondary prophylaxis among heart patients affected with rheumatic heart disease attending Mulago Hospital. *Cardiovascular Journal of Africa* 2013; **24**(4): 124-9.
199. Huck D, Nalubwama H, Longenecker C, Frank S, Okello E, Webel A. A qualitative examination of secondary prophylaxis in rheumatic heart disease. *Global Heart* 2015; **10**(1): 63-9.
200. New Zealand Ministry of Health. Guidance for Administering an Intramuscular Injection of Benzathine Benzylpenicillin.
201. Amir J, Ginat S, Cohen YH, Marcus TE, Keller N, Varsano I. Lidocaine as a diluent for administration of benzathine penicillin G. *Pediatric Infectious Disease Journal* 1998; **17**(10): 890-3.
202. Emami Zeydi A, Khezri HD. Can Lidocaine be Safely Used to Reduce Pain Caused by Intramuscular Penicillin Injections? A Short Literature Review. *Oman Medical Journal* 2012; **27**(4): 337.
203. Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. *Journal of Global Health* 2013; **3**(1): 010303.
204. Kingston M, French P, Goh B, et al. UK national guidelines on the management of syphilis 2008. *International Journal of STD and AIDS* 2008; **19**(11): 729-40.
205. Russell K, Nicholson R, Naidu R. Reducing the pain of intramuscular benzathine penicillin injections in the rheumatic fever population of Counties Manukau District Health Board. *Journal of paediatrics and child health* 2014; **50**(2): 112-7.
206. Bass JW, Longfield JN, Jones RG, Hartmann RM. Serum levels of penicillin in basic trainees in the US Army who received intramuscular penicillin G benzathine. *Clinical infectious diseases* 1996; **22**(4): 727-8.
207. Thamlikitkul V, Kobwanthanakun S, Pruksachitvuthi S, Lertluknithi R. Pharmacokinetics of Rheumatic Fever Prophylaxis Regimens. *Journal of International Medical Research* 1992; **20**(1): 20-6.
208. Currie BJ, Burt T, Kaplan EL. Penicillin concentrations after increased doses of benzathine penicillin G for prevention of secondary rheumatic fever. *Antimicrobial Agents and Chemotherapy* 1994; **38**(5): 1203-4.
209. Kaplan EL, Berrios X, Speth J, Siefferman T, Guzman B, Quesny F. Pharmacokinetics of benzathine penicillin G: Serum levels during the 28 days after intramuscular injection of 1,200,000 units. *The Journal of Pediatrics* 1989; **115**(1): 146-50.
210. Broderick MP, Hansen CJ, Faix DJ. Factors associated with loss of penicillin g concentrations in serum after intramuscular benzathine penicillin G injection: A meta-analysis. *Pediatric Infectious Disease Journal* 2012; **31**(7): 722-5.
211. Kassem AS, Zaher SR, Shleib HA, El-Kholy AG, Madkour AA, Kaplan EL. Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two-week versus four-week regimens: comparison of two brands of BPG. *Pediatrics* 1996; **97**(6): 992-5.
212. Chen Rh, Yang L, Liu M. Analysis of Crystal Properties and Pumping Needle Experiment of 2 Kinds of Benzathine Benzylpenicillin. *China Pharmacy* 2013; **24**(9): 784-6.
213. Loreto-Garin JP. Voluntary Recall of Specific Lots of Benzathine Benzylpenicillin (ZALPEN) 1,200,000 Units per Vial Sterile Powder for Injection (I.M.). In: Health Do, editor.: Republic of the Philippines; 2015.
214. World Health Organization. Antimicrobial resistance: Fact sheet No. 194. 2015. <http://www.who.int/mediacentre/factsheets/fs194/en/> (accessed 9 May 2016 2016).
215. Durand M, Wistaff R, Leloir J. Penicillin to prevent recurrent leg cellulitis. *New England Journal of Medicine* 2013; **369**(9): 880.
216. Stamm LV. Global Challenge of Antibiotic-Resistant Treponema pallidum. *Antimicrobial Agents and Chemotherapy* 2010; **54**(2): 583-9.
217. Myint M, Bashiri H, Harrington RD, Marra CM. Relapse of Secondary Syphilis after Benzathine Penicillin G: Molecular Analysis. *Sexually Transmitted Diseases* 2004; **31**(3): 196-9.
218. Kahn F, Rasmussen M. Penicillin-resistant Streptococcus pyogenes? *FEMS Microbiology Letters* 2012; **326**(1): 1.
219. Steer A, Danchin M, Irlam JH, et al. Primary prevention of rheumatic fever in children: Key factors to consider. *SAMJ: South African Medical Journal* 2014; **104**(3): 156-7.
220. Passàli D, Lauriello M, Passàli GC, Passàli FM, Bellussi L. Group A Streptococcus and its antibiotic resistance. *Acta Otorhinolaryngologica Italica* 2007; **27**(1): 27-32.
221. Cimolai N. Streptococcus pyogenes is alive and well. *BC Medical Journal* 2009; **51**: 122-7.
222. Horn DL, Zabriskie JB, Austrian R, et al. Why have group A streptococci remained susceptible to penicillin? Report on a symposium. *Clinical infectious diseases* 1998; **26**(6): 1341-5.
223. Bilavsky E, Eliahou R, Keller N, Yarden-Bilavsky H, Harel L, Amir J. Effect of benzathine penicillin treatment on antibiotic susceptibility of viridans streptococci in oral flora of patients receiving secondary prophylaxis after rheumatic fever. *Journal of Infection* 2008; **56**(4): 244-8.
224. Aguiar AAd, Sampaio RO, Sampaio JldM, et al. Effect of penicillin G every three weeks on oral microflora by penicillin resistant Viridans Streptococci. *Arquivos brasileiros de cardiologia* 2012; **98**(5): 452-8.
225. Albrich WC, Monnet DL, Harbarth S. Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. *Emerg Infect Dis* 2004; **10**(3): 514-7.
226. Leach AJ, Morris PS, Smith-Vaughan H, Mathews JD. In vivo penicillin MIC drift to extremely high resistance in serotype 14 Streptococcus pneumoniae persistently colonizing the nasopharynx of an infant with chronic suppurative lung disease: A case study. *Antimicrobial agents and chemotherapy* 2002; **46**(11): 3648-9.
227. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. *The Lancet infectious diseases* 2013; **13**(12): 1057-98.
228. Central Australian Rural Practitioners Association. CARPA Standard Treatment Manual: A clinic manual for primary health care practitioners in remote and Indigenous health services in central and northern Australia. Alice Springs, NT Australia: Central Australian Rural Practitioners Association; 2014.
229. European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/07/WC500147002.pdf (accessed 11 May 2016 2016).
230. Silva KGdH. Mise au point et développement des systèmes lipidiques émulsionnés contenant la benzathine penicilline G: Paris 11; 2010.
231. Wang Y. Antibiotic-conjugated polyacrylate nanoparticles: New opportunities for development of anti-MRSA agents: ProQuest; 2006.
232. Hedley L, Panesar P. Play your part in managing syphilis. *Pharmaceutical Journal* 2012; **289**(7722): 263.
233. Theuretzbacher U, Van Bambeke F, Cantón R, et al. Reviving old antibiotics. *Journal of Antimicrobial Chemotherapy* 2015: dkv157.
234. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route. Guidance for Industry and Review Staff. Good Review Practice In: Administration FaD, editor.; 2015.
235. World Health Organization. Immunization, Vaccines and Biologicals: WHO Preferred Product Characteristics. 2016. http://www.who.int/immunization/research/vaccine_preferred_product_characteristics/en/ (accessed 11 May 2016 2016).
236. World Health Organization. Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings. Geneva: World Health Organization, 2010.
237. World Health Organization. Essential medicines and health products: National Pharmacovigilance Centres. 2016. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/nat_centres/en/ (accessed 11 May 2016 2016).

info@rhdaction.org

** [@RHDAction](https://twitter.com/RHDAction)
[#RHDACTION](https://twitter.com/RHDAction)**

www.rhdaction.org